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1. INTRODUCTION  
1.1 The Chemokine System 
Chemotactic signalling networks between resident cells within the tissue and migrating cells are 
essential in developmental biology and immunology where proper positioning of cells is crucial for 
lymphopoiesis, lymphoid organ development (1) or for mounting effective immune responses.(2-4) 
The human immune system, consisting of an innate and an adaptive branch, is a complex and tightly 
regulated network of migrating and resident cells which is able to distinguish between non-dangerous 
self, non-dangerous-foreign and dangerous-foreign. The more ancient innate immunity is germ-line 
encoded and can bind bacterial and viral pathogens via pattern recognition receptors on their surface 
or within the cytoplasm. Macrophages, dendritic cells (DCs) and neutrophils represent innate immune 
effectors and serve as first line of defence against pathogens. The more recently emerged adaptive 
immune system is instructed during the lifespan of an individual. Exposure to different antigens leads 
to rearranged pathogen-specific surface receptors on B cells (B cell receptor) and T lymphocytes 
(T cell receptor) and the generation of memory B and T cells which elicit fast and powerful immune 
responses upon second encounter with the same pathogen. The ability of continuous rearrangement of 
surface receptors and the development of memory are hallmarks of the adaptive immunity.  
Key players in migration, homing and retention of immune cells are chemotactic cytokines, so called 
CHEMOKINES, small secreted proteins ranging from 67 to 127 amino acids. The presence of four 
cysteine residues in conserved locations is crucial for the formation of disulfid bonds and 
therefore of their 3-dimensional shape.(5) Chemokines exert their biological effects by interacting 
with G protein-coupled seven transmembrane domain receptors that are selectively expressed on the 
surfaces of their target cells. Following interaction with their specific chemokine agonists, chemokine 
receptors undergo conformational changes and trigger a cascade of events, including flux of 
intracellular calcium (Ca2+) ions (calcium signaling), phosphorylation of cytoplasmatic kinases, 
cytosceletal rearrangements, chemotaxis and activation of cell adhesion molecules such as intergrins. 
Some chemokine receptors can bind several chemokines with different affinities, such as CCR5, 
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indicating a certain redundancy or robstness of the sytem, other chemokine receptor, such as CXCR4, 
bind only one chemokine, the CXCL12. 
Up to date, more than 40 chemokines and more than 20 chemokine receptors have been identified. 
In vivo, chemokines are thought to be released and bound to extracellular matrix proteins and 
glycosaminoglycans in the environment, creating a gradient indispensable for inducing cell migration. 
(6) The first protein to be identified as a chemoattractant in 1987 was CXCL8 (IL-8, NAP-1) that was 
shown to selectively recruit neutrophils.(7,8) Its receptor, CXCR1, was the first chemokine receptor to 
be cloned (9) followed by the identification of a second CXCL8 receptor, CXCR2.(10,11) 
Migration is controlled by the expression of different chemokine receptors on the cell surface, which 
can be modulated upon maturation or differentiation. As an example, different types of immature DCs 
are localized at strategically important points of the body and serve as guardians against invading 
pathogens. They can also be recruited from blood at inflammatory sites, using chemokine receptors 
like CCR1 or CCR5. Upon antigen encounter, DCs get activated, downmodulate CCR1 and CCR5, 
and upregulate a specific chemokine receptor, CCR7, which allows them to migrate from the 
periphery into the T cell areas within draining secondary lymphoid organs where the appropriate 
ligand, CCL21, is expressed.(12-16) Here, activated DCs can activate naïve T and B cells which are 
specific for the antigen presented by the dendritic cell by a process known as antigen presentation. In 
this way an adaptive immune response can be initiated with the generation of antigen-specific T and 
B cell as well as antibody producing plasma cells.(17) Similar to activated dendritic cells, T and 
B lymphocytes also change their chemokine receptor profile upon activation, and become responsive 
to different chemokines which control the proper immune response.(18-20) All migratory processes of 
immature and mature dendritic cells, as well as naïve and activated B and T cells within and outside 
secondary lymphoid organs are orchestrated by a variety of chemokines, expressed at distinct time 
points, at distinct location, and by distinct cell types within the tissues. This crosstalk between 
chemokine expressing cells and their responding counterparts is essential to mount an adequat immune 
response.(21) Inappropriate activation of the chemokine network is associated with various 
pathological conditions such as autoimmunity, graft rejection or artheriosclerosis.(22)  
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Initially, newly discovered chemokines have been given a name according to their function 
(e.g.: MIG = Monokine Induced by Gamma Interferon; SDF-1 = Stromal-Derived Factor-1). Over the 
years, the proliferation of chemokine aliases that has accompanied the discovery of chemokines by 
multiple groups using bioinformatics, led to the development of a nomenclature system that parallels 
the receptor nomenclature. Chemokines were also classified accordingly to their functions in 
homeostatic and inflammatory. Even if this classification facilitates the understanding of the 
chemokine network, it does not correctly represent chemokine functions as several chemokines have 
been shown to exert a dual function activity.  
 
1.1.1 Classification of chemokines by function 
This classification distinguished chemokines which either function under homeostatic or 
inflammatory conditions.(23) Soon after, it became clear that some chemokines have a dual-
function: they are expressed in homeostatsis as well as in inflammation.(24) Homeostatic 
chemokines, constitutively expressed, comprise molecules acting in primary and secondary lymphoid 
organs (25-27) as well as peripheral tissues.(28,29) In the bone marrow and in the thymus, for 
instance, homeostatic chemokines control the correct positioning and trafficking of committed 
lymphoid progenitor cells into “niches” to guarantee full maturation and functionality.(30-32) In 
addition, the development of secondary lymphoid organs (e.g. Peyer’s Patches and inguinal lymph 
nodes) is crucially dependent on the function of homeostatic chemokines.(33,34) Distinct T and B cell 
attractant chemokines in secondary lymphoid organs ensure the accurate segregation into T cell areas 
and B cell follicles. This segregation is essential for the initiation of adaptive immune responses. 
(33,35) In addition to directional guidance, homeostatic chemokines contribute to non-directional 
T cell migration (chemokinesis) within lymph nodes, thus promoting faster, more widespread 
movements of T cells to enhance the probability to encounter the specific antigen presenting dendritic 
cell.(36-38)  
Inflammatory chemokines are induced upon inflammatory processes like bacterial and viral infections 
and control the recruitment of immune effectors to inflamed target tissues. Upon stimulation with pro-
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inflammatory cytokines (e.g. IL-1, TNF) or bacterial and viral products (e.g. CpG, LPS) many cell 
types including leukocytes and stromal cells can upregulate the expression of a variety of 
inflammatory chemokines, which represents a “come-and-help-us” signal to other cell types. Under 
inflammatory conditions a variety of chemokines are upregulated and it is therefore likely that 
responding leukocytes are simultaneously exposed to a variety of inflammatory and homeostatic 
chemokines at the same time. The mechanism, how leukocytes integrate different simultaneous 
chemoktactic signals over their chemokine receptors and how they respond to them, is still poorly 
understood.  
Dual-function chemokines play essential roles in guiding precursors and resting mature leukocytes to 
sites of leukocyte development and immune surveillance and in addition, are up-regulated during 
immune responses and target effector cells.(23) In addition, specific organs like the intestine are 
constantly exposed to an enormous number of microbes and may therefore express inflammatory 
chemokines even under homeostatic conditions.(39)  
 
1.1.2 Classification of chemokines by structure 
Over the years, the continous discovery of new chemokines led to confusion in the field since different 
groups concomitantly identified the same chemokine giving it a different name according to the 
function described. A new way of designating chemokines was introduced and summarized by Zlotnik 
and Yoshie in 2000.(5) The new classification is according to chemokine structural characteristics. 
Chemokines share four conserved cysteines which are essential for their tertiary structure, of which 
two are in their N-terminal domain and are adjacent or separated by one amino acid. Based on these 
first two cysteins, chemokines are classified into 2 major subfamilies, the CC chemokines and the 
CXC chemokines. The majority of chemokines fall into one or the other group. Most of the 
CC chemokines have been mapped on human chromosome 17q11-2 (40) while the majority of the 
CXC chemokine genes are clustered on human chromosome 4q12-21.(41) In addition to the 2 major 
subfamilies, there are two other classes of chemokines that have been described so far: the CX3C 
chemokine, fractalkine, and the C chemokine, lymphotactin. Fractalkine, one of the two membrane-
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bound chemokines with a mucin-like stalk, has three amino acids between the first two cysteines (42) 
whereas lymphotactin misses the first and the third cysteine.(43) 
Chemokines from the CC chemokine family act in a broad range on different cell types including 
monocytes, T lymphocytes, DCs, basophils and eosinophils. An important feature of the chemokine 
system is illustrated in Table1: redundancy versus robustness. One chemokine can bind different 
receptors and in reciprocal, one receptor can bind different chemokines. This adds an additional step in 
the complexity of cellular migration. 
 
Table 1. CC Chemokine family 
 
CC Chemokines and their receptors. The first column indicates the chemokine name according to the 
structure. The second column indicates the historical chemokine name according to its function. The third 
column indicates the chemokine receptors which can bind the chemokine. The last column groups the 
chemokines according to their mode of action into homeostatic (H), inflammatory (I) or dual-function (D) 
chemokines.  
 
The second major subfamily of chemokines is the group of CXC chemokines (Table 2) which can be 
further subcategorized based on the presence of the tripeptide motif Glu(E)-Leu(L)-Arg(R), into ELR+ 
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or ELR- chemokines. ELR+ chemokines (CXCL1, CXCL2, CXCL3, CXCL5 to CXCL8) have been 
reported to act on neutrophils and are also angiogenic (44,45), whereas ELR- chemokines (CXCL4, 
CXCL9 to CXCL14) activate different leukocytes (T and B lymphocytes) and are angiostatic.(46)  
 
Table 2.  CXC, C and CX3C chemokine families 
 
CXC, CX3C and C chemokines and their receptors. The first column indicates the chemokine name according 
to the structure. The second column indicates the historical chemokine name according to its function. The third 
column indicates the chemokine receptors which can bind the chemokine. The last column groups the 




1.1.3 Lymphocyte trafficking under homeostatic conditions  
Interaction between chemokine and chemokine receptor alone are not sufficient to induce cell 
migration into the tissue. Transmigration of a leukocyte into the tissue is rather a multi-step process 
which can be divided in 4 different steps: 1) tethering and rolling, 2) activation, 3) firm adhesion and 
spreading, 4) intravascular crawling and transcellular transmigration into the tissue (Figure 1). 
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Thethering and rolling is mainly dependent on selectins, whereas activation of integrins depends on 
chemokines. Upon chemokine interactions, cells adhere firmly to the endothelium via integrin 
activation and start to transmigrate into the tissue. 
 
Transmigration of cells strongly depends on chemokine interactions. Various chemokines can be 
transported or bound onto the luminal site of endothelial cells and in this way influence migratory 
behaviour of circulating leukocytes under homeostatic or inflammatory conditions.(47) On the luminal 
site of the endothelium, chemokines play an important role in the transmigration of cells by inducing 
integrin activation, which leads to tight binding between transmigrating cell and endothelial cell.(48)  
At birth, our lymphocyte compartment consists mainly of naïve, antigen-unexperienced cells. During 
lifetime, our memory pool of B and T lymphocytes is constantly increasing so that adult individuals 
have a mixture between naïve lymphocytes, which have not seen their specific antigen yet and 
memory lymphocytes, which have already encountered their specific antigen during a previous 
infection and are now patrolling through the body. Naïve as well as memory lymphocytes have the 
ability to circulate through the blood and transmigrate into peripheral lymphoid organs or peripheral 
tissue, screening for specific antigens or antigen presenting cell, which would activate them via the 
B or T cell receptor on their cell surface. The route of homing/patrolling through secondary lymphoid 
Figure 1: Multistep transmigration of leukocytes from vessels into the tissue 
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organs and peripheral tissues is regulated by the chemokine receptor expression on the surface and the 
expression pattern of the cognate agonists in the tissue.  
Under homeostatic conditions, lymphocytes enter the lymph node from the blood via a specialized 
type of postcapillary venules, the high endothelial venules (HEV). On the luminal site, HEVs 
specifically express the CD62L-ligand peripheral node addressin (PNAd) as well as the CCR7-ligand 
CCL21. Transmigration is initiated by a tethering step that allows leukocytes to loosely bind to 
endothelial cells. This step is mediated by L-selectin (CD62L) expressed on lymphocytes that interacts 
with its endothelial ligand peripheral node addressin (PNAd). Subsequently, CD62L-dependent 
lymphocytes rolling on the endothelium is followed by chemokines recognition via the appropriate 
chemokine receptor.(21,49) Chemokine receptor triggering induces intracellular signals that activate 
integrins from a low affinity to a high affinity state (inside-out-signal). In this case, the homeostatic 
chemokine CCL21, ligand of CCR7, mediates the activation of the integrin Leukocyte Function-
associated Antigen 1 (LFA-1) on rolling T cells which in turn interacts with its ligand, the 
InterCellular Adhesion Molecule-1 (ICAM-1) on HEVs.(50) Upon activation of integrins, 
lymphocytes firmly stick to the endothelium and transmigrate into the tissue (Figure 1). After 
transmigration into the lymph node, naïve CD4+ T cells migrate towards the T cell areas (paracortex) 
where the ligands for CCR7, CCL19 and CCL21, are expressed by stromal cells.(51) In this area, they 
actively move by chemokinesis and scan for antigen-bearing DC.(36-38). Not only chemokinesis is 
important in cell-cell contact in the T area, but also release of selective chemokines has been shown to 
guide naïve CD8+ T cells to APCs in a CCR5 dependent manner.(52) In contrast to naïve T cells, 
naïve B cells express lower levels of CD62L.(53) Rolling B cells can be induced to arrest on HEVs by 
either CCR7 or CXCR4 agonists. After transmigration, B cells migrate in a CXCR5-dependent 
manner towards the B cell areas where its cognate agonist CXCL13 is produced by follicular dendritic 
cells (FDC) and TFH cells. 
B and T cells that have entered a lymph node exit through the medulla via efferent lymphatics.(54-57) 
This active process of re-circulation ensures that lymphocytes can be exposed to their cognate antigen 
independently on where the pathogen has been sampled.  
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A key player among chemokines in lymphopoiesis and immune homeostasis is the house-keeping 
chemokine CXCL12, together with its cognate receptor CXCR4.(58,59) CXCL12 as well as CXCR4 
are the only chemokines/chemokine receptors identified so far, which has been shown to be pivotal for 
life, since gene targeted disruption of CXCR4 or CXCL12 leads to perinatal death in mice.(60,61) 
Various physiological as well as pathological processes have been shown to depend on the 
CXCL12/CXCR4 axis. The chemokine receptor CXCR4 is the coreceptor for HIV entry in human 
CD4+ T cells.(58,59,62) Stromal cell-derived CXCL12 has a crucial role within the bone marrow 
(BM). B cell maturation occurs in complex BM microenvironments known as bone 
marrow niches.(63) Reports in gene-targeted mice where CXCR4 was selectively deleted in B cells, 
have documented its requirement for retention of B cell precursors in the BM.(64) CXCL12 is 
therefore not only important for B cell migration, but also for trapping of B cells within the BM 
environment. CXCR4- and CXCL12-deficient animals exhibit deficient B cell development and a lack 
of bone marrow myelopoiesis.(60) During their maturation in the bone marrow, B cells highly express 
CXCR4 yet gradually loose their responsiveness to CXCL12 which could account for the release into 
circulation. (65,66) Hematopoietic stem cells (HSC) in the bone marrow also depend on stromal-
derived CXCL12 and blocking CXCL12/CXCR4 interactions in the bone marrow leads to a release of 
different progenitors into the circulation.(67-71) Only recently, the CXCR4-inhibitor (AMD3100, 
Plerixafor) has been introducded in clinical protocols to increase circulating hematopoietic progenitors 
before bone marrow transplantation.(72,73)  In addition to its niche-like signal for HSCs in the bone 
marrow, CXCL12 is an important survival factor for B cells and plasma cells and is essential for 
plasma cell homing to the bone marrow.(74,75)  Another important function of CXCL12 in B cell 
biology is during an adaptive immune response where CXCL12 together with CXCL13 seem to 
regulate germinal center B cell trafficking between dark and light zone.(76) 
More recently CXCR7 has been described as a second receptor for CXCL12 (77) Mice with gene 
targeted deletion of CXCR7 succumb perinatally due to ventricular septal defects in the heart while 
hematopoiesis including B cell development was not affected.(61) In zebrafish development, CXCR7 
seems to function as a non-signaling scavenging receptor, which internalizes CXCL12 from the 
environment and regulates in this way its extracellular concentration.(78) 
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Another B cell attractant chemokine is CXCL13 which acts on the chemokine receptor CXCR5, 
expressed on B cells and a subset of activated T cells. It is produced and released by germinal center 
T cells and FDCs in the germinal center. This germinal center T cell subset is called follicular B helper 
T cells (TFH) and is localized in the light zone of the germinal center, where they provide help to 
germinal center B cells to differentiate towards memory B or plasma cells.(79) CXCL13 is specifically 
expressed by follicular dendritic cells (FDC) in the light zone of the germinal center and is essential 
for B cell migration into B cell follicles in lymph nodes and in the spleen.(27,33,76) Knock out mice 
deficient in CXCR5 show a disrupted T/B cell segregation and fail to develop inguinal lymph nodes 
and Peyer’s Patches demonstrating a chemokine-driven positive feedback loop that is essential to 
develop some secondary lymphoid organs.(33,34)  
 
1.1.4 Lymphocyte trafficking under inflammatory conditions 
 
Depending on the type of pathogen, cell-to-cell signals received from the antigen presenting cells 
(APC) as well as environmental influences, T cells can differentiate into different T cell subsets. Up to 
date 5 such T helper subsets have been described, Th1, Th2, Th17, natural and induced regulatory 
T cells (Tregs) and follicular B helper T cells (TFH) cells. The differentiation into each subset depends 
on distinct cytokine signals in the environment and the induction of specific transcription factors 













Figure 2: Effector T cell differentiation and the 
expression of transcription factors, effector 
cytokines, and chemokine receptors. Transcription 
factors for each subset have been placed in the 
nucleus. The list of chemokine receptors, or 
cytokines, for each of the subsets is not complete. 
(from King et al. Ann. Rev Imm 2008, 26:741-66) 
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Each T cell subset releases specific cytokines and expresses a different repertoire of chemokine 
receptors. Viruses and intracellular bacteria induce mainly Th1 responses. Th1 lymphocytes release 
IFN-γ and IL-2. A Th1 response activates mononuclear phagocytes and promotes isotype switching. 
Th2 cells, in contrast, are induced during parasite and helminth infection, produce IL-4 and IL-5 and 
are involved in responses mediated by IgE, eosinophils and basophils. Fungi tend to induce a Th17 
differentiation, where T cells mainly express IL-17 and IL-22. While Th1, Th2 and Th17 are favoring 
an inflammatory environment by releasing a variety of proinflammatory cytokines, a fourth subset of 
Treg can dampen an immune response by releasing anti-inflammatory cytokines such as IL-10 and 
TGF-β. A fifth group comprises TFH: this subset is found within the light zone of the germinal centers 
where they provide costimulatory help to late germinal center B cells.  TFH cells are characterized by 
their expression of the B cell attractant chemokine CXCL13, CD57 and depend on the transcriptioin 
factor BCL6.(80-82) Whether T cell differentiation is a one way road, or whether plasticity between 
T cell subsets occur in vivo is subject of intense research. Past studies emphasized terminal 
commitment of effector T cells. (83-86) More recently it has become clear that flexibility between 
T cell subsets is probably not an exception. (87) Beside their different cytokine expression, T cell 
subsets also differ in their chemokine receptor profiles and show therefore different migratory 
capacities.(88-90) The upregulation of CXCR5 for instance enables TFH cells to migrate towards the 
T/B cell border where they can interact with the appropriate B cell in a cognate fashion. In contrast to 
T cells, follicular B cells can upregulate CCR7 upon engagement of their antigen-receptor, which 
induces B cell migration towards the T/B border.(91) Interestingly, activated follicular B cells do not 
seem to downregulate CXCR5 expression but the upregulation of CCR7 seems to be sufficient to 
induce B cell migration to the B/T cell- zone boundary to seek for costimulatory help by follicular 
helper T cells (TFH). During plasma cell differentiation, activated B cells upregulate CXCR3 and 
CXCR4, which allows them to home into the bone marrow or into inflamed peripheral tissues 
(Figure 3).(92)  
 
 




Figure 3. CXCR4- and CXCR3- depedent migration during plasma cell differentiation. B cells are 
generated in the bone marrow and exit as precursor B cells (pre-B cells), which are immature and express IgM. 
These cells further mature into naive B cells and then into either marginal-zone B cells or follicular B cells. 
When activated, these marginal-zone and follicular B cells can differentiate into plasmablasts and short-lived 
plasma cells, both of which can secrete antibody. Alternatively, with the help TFH cells, follicular B cells can also 
differentiate into memory B cells, which are long-lived, and express antibodies of switched class and high 
affinity for antigen. When reactivated by antigen, memory B cells can differentiate into plasmablasts, which are 
competent to become long-lived plasma cells. A small proportion of these plasmablasts stay in the secondary 
lymphoid organ (the spleen or the lymph node) where they were generated. Most of the plasmablasts migrate 
either to inflamed tissue, under the control of the CXC-chemokine receptor 3 (CXCR3; which binds CXC-
chemokine ligand 9 (CXCL9), CXCL10 and CXCL11), or to the bone marrow, under the control of chemotaxis 
towards CXCL12 (which binds CXCR4). All three tissues have finite numbers of plasma-cell survival niches. 
Plasmablasts that succeed in the acquisition of such a niche differentiate into plasma cells and become immobile. 
Resolution of inflamed tissue after a successful immune response terminates the survival niches in the tissue and 
therefore eliminates the resident plasma cells, and this is the peak of the immune response. In the bone marrow, 
and to a lesser degree in secondary lymphoid organs, long-lived plasma cells survive and provide humoral 
memory. (from Radbruch et al. Nat. Rev. Imm. 2006, 6:741-50) 
 
 
Beside activated B cells, also activated CD4+ and CD8+ T cells, plasmacytoid DCs and NK cells 
express CXCR3 and CXCR4 and can respond to inflammation-induced chemokines CXCL9, CXCL10 
and CXCL11.(93,94) Under inflammatory conditions, cell migration within draining lymph nodes 
undergoes rapid changes. Different cell types can be recruited to inflamed lymph nodes also in a 
CXCR3-dependent manner.(95-97). Of note, there is strong evidence that the place of chemokine 
expression does not always correlates with the mRNA expression and that transcytosis of chemokines 
is an important functional mechanism for cell recruitment.(98-101) 
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1.1.5 Chemokines and chemokine receptors in haematological malignancies 
After malignant transformation, tumor cells can retain their chemokine receptor profile or can 
produce chemokines.(102) Malignant cells, in general, express distinct and non-random 
patterns of chemokine receptors, which render the tumor able to respond to chemokines in the 
environment, and favor its infiltratation and dissemination into different organs following a 
chemokine gradient. The first evidence that chemokine receptors are used by tumor cells for 
metastatic dissemination came from the work of Müller and colleagues that showed the 
involvement of CXCR4 in breast cancer metastasis.(103) More recently a role for chemokine 
receptors has also been found in a variety of haematological malignancies. Lymphocyte 
leukemias and B cell lymphomas express several chemokine receptors, including CCR6, 
CCR7, CXCR3, CXCR4, and CXCR5.(24,104-108) In addition, expression of various 
chemokines has been detected in a variety of human B cell lymphomas (24,109,110), follicular 
dendritic cell sarcomas (111), and in T-cell lymphomas, such as Angioimmunoblastic T-cell 
Lymphoma, which is thought to derive from germinal center T cells.(112) Of note, most of the studies 
assessed mRNA expression by rt-PCR or micro-array analyis and therefore neglect, that tumors 
include a variety of bystander cells, such as stromal, endothelial and immune effector cells which may 
contribute to the upregulation of gene products. Detailed histopathological examination of chemokine 
expression within the tumor and its environement is required to improve our understanding on the 
complex relationship between tumor cells resident their bystander cells in the microenvironment.  
 
1.1.6 Synergistic activities among chemokines 
Up to date, in vitro and in vivo studies have evaluated cell migration induced by a single chemokine. 
However, under homeostatic and inflammatory conditions, leukocytes are exposed to variety of 
chemoattractans at the same time. Moreover, leukocytes often express several chemokine receptors on 
their surface and can therefore receive different chemoattractant stimuli at the same time. The 
mechanisms, how leukocytes integrate signals from the environments and respond to simultaneous 
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stimulation with different chemokines are not well understood. For instance, immature B cells express 
CCR2 and CXCR4 and while CXCL12 induces a strong response when added as first chemokine, the 
pre-treatment with CCL2 diminishes CXCL12-induced activation.(113) In other words, the duration, 
the concentration and the timing of a first stimulation can make a cell refractory to further 
engagements by other ligands. The concomitant presence of two ligands, in contrast, can induce a 
response that exceeds additive effects. Such synergistic activity represents on amplification 
mechanism that is only active once a cell encounters two ligands at the same time. This mode of action 
could represent a “security code” that ensures that powerful effects are only generated in response to 
the right combination of ligands. Moreover, the first ligand could sensitize the cells to respond to a 
second stimulus.(114,115) These cells have an advantage compared with unstimulated cells that can 
lead to better activation or even survival. Synergistic activites between chemokines include two 
separate mechanisms: in the first scenario a leukocyte is exposed to different chemokines, for which 
the cell expresses the cognate chemokine receptors. In a second scenario a leukocyte is exposed to a 
variety of chemokines but expresses only the chemokine receptors selective for a single chemokine. 
One of the first reports on synergistic activities between chemokines demonstrated that regakine-1, a 
CC chemokine isolated from bovine serum, could synergise with CXCL8 and CCL7 in the recruitment 
of neutrophils and lymphocytes, respectively.(116) Alternatively, plasmacytoid DC (pDCs) responded 
synergistically to suboptimal concentrations of CXCL12 and CXCL10.(117) Even more striking, the 
presence of CXCL10 in the upper well of the chemotaxis chamber seemed to prime the cells to 
migrate to low CXCL12 concentrations and excluded the involvement of a CXCL10 chemokine 
gradient. Since pDCs express the specific receptors, the synergistic effect was believed to be mediated 
by both CXCR3 and CXCR4.(114) These observations were followed by several studies in vitro and 
in vivo.(118,119) A different mode of synergism has been identified by various groups whereby the 
responses of cells can be influenced by the presence of non-ligand chemokines. In this case, cells 
bearing receptors for one chemokine, strongly respond to a suboptimal agonist concentration in the 
presence of a non-ligand chemokine.(120-122) Different cellular responses, such as adhesion assays, 
chemotaxis, receptor internalization and the activation of intracellular signalling cascades, were 
addressed and all showed increased responses when a non-ligand chemokine was present. The 
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depicted chemokines were chosen also because of their relative distribution in vivo. CXCL13 and 
CCL21 are both expressed in secondary lymphoid organs and the migration of antigen-experienced 
T cells to the B/T- cell boundary zone could potentially be enhanced by CXCL13.(121) CCL22, the 
agonist of CCR4, is concomitantly expressed with the synergy-inducing chemokine CXCL10 in atopic 
and allergic dermatitis, and skin-homing CCR4+ T cells could benefit from the co-presence of both 
chemokines.(122) CXCL4 and CCL5 are two chemokines stored in platelets and are released upon 
activation. The arrest of monocytes under flow conditions, mediated by CCL5, could be enhanced 
when CXCL4 was applied at the same time.(120) The receptor for CXCL4, recently identified being 
CXCR3B (123) is not expressed on monocytes (124) and therefore does not contribute to the 
synergistic effect. These studies could show that the agonist and the synergy-inducing chemokine can 
form heteromeric complexes, suggesting that the synergy-inducing chemokine could fix the agonist in 
the best conformation for triggering.  The structural requirements for the formation of heterodimers 
were elucidated and showed for the CCL22/CCL7 and CCL5/CXCL4 complexes.(111,122,125) 
Moreover, disrupting heterocomplexes formation between CCL5 and CXCL4 in vivo inhibits 
monocyte recruitment into artheriosclerotic plaques.(125) 
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1.2 B Cell Physiology and Lymphomagenesis 
1.2.1 B cell trafficking  
Trafficking of B cells to LNs and Peyer’s patches (PPs) through HEV involves, similar to T cells, a 
combination of chemokine receptors, such as CCR7 and CXCR4, and adhesion molecules. 
(33,126,127) In contrast to T cells, B cell homing to LNs is mainly directed by CXCR4. B cell-HEV 
interactions are largely unaffected by the absence of functional CCR7.(128) However, simultaneous 
absence of CXCR4 and CCR7 eliminates most B-cell homing to sencondary lymphoid organs.(126) 
PPs have an additional level of control for B cell homing. In addition to CCR7 and CXCR4 signaling, 
CXCR5 contributes to B cell homing to PPs and to the positioning of B cells in the B area of the LNs. 
(33,126). Activated B cells within B cell follicles upregulate the chemokine receptor CCR7 which is 
guiding the cells to the T/B border where the CCR7 agonists are present, to allow T/B cell 
interactions.(129)  B cell trafficking to non-lymphoid organs is less understood. B cell homing to 
selective tissues is controlled by the expression of distinct receptors. For example, a subset of 
differentiated IgA+ B cells expresses the chemokine receptor CCR10, which is only rarely expressed 
by B cells that secrete other immunoglobulin isotypes. This B cell subtype trafficks to mucosal tissues 
where CCL28, the agonist of CCR10 is preferentially expressed.(130-132) During their final 
differentiation to plasmablasts, activated B cells upregulate CXCR3 and become responsive to the 
CXCR3-ligands CXCL9, CXCL10 and CXCL11.(92) This pattern of receptor expression seems to be 
important for early plasma cell migration to site of inflammation.  
 
1.2.2 B cells during germinal center formation  
The hallmark of adaptive immune responses is specificity and memory towards encountered antigens. 
Specificity and memory require gene rearrangement and recombination events within lymphocytes. 
These events have to be strictly regulated because they harbour an increased risk for malignant 
recombination events and therefore malignant transformation of normal lymphocytes. The majority of 
malignant lymphomas in humans derive from B cells, which undergo malignant transformation at a 
certain timepoint during their development. The germinal center microenvironment is the main source 
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of memory B cell and plasma cells that produce high-affinity antibodies, which are necessary to 
protect against invading microorganisms.(133) The beneficial role of germinal center B cells in 
immunity is somewhat counterbalanced by their detrimental role in lymphomagenesis, as the majority 
of B cell lymphomas originate from germinal center B cells (Table 4).(134,135) In fact, with the 
exception of the rare lymphblastic and mantle-cell lymphoma subtypes, most B cell non-Hodgkin 
lymphomas (B-NHL) display somatically rearranged IgV genes, indicating that they are derived from 
B cells that are blocked within or have passed through the germinal center.(134,135) The genomes of 
these B-NHL subtypes display two main types of genetic lesions – chromosomal translocations and 
aberrant somatic hypermutation, (ASHM) – which represent mistakes in the immunoglobulin gene 
remodelling mechanisms. (136) Of note, as SHM can also occur outside of the GC, extrafollicular 
B cells may represent the targets of malignant transformation in certain subtypes of lymphoma.(137-
139) The initiation of the GC response requires the interaction of co-stimulatory B-cell-surface 
receptors with ligands expressed by T cells and/or antigen-presenting cells, of which the most 
important is that between the tumour-necrosis factor (TNF)-receptor family member CD40, which is 
expressed by all B cells, and its ligand CD154 expressed by helper T cells. Activated B cells can then 
either develop directly into antibody-secreting cells in specialized extrafollicular sites of plasmablast 
growth and differentiation, such as the medullary cords of lymph nodes, or mature into GC-precursor 
B cells and move to the primary follicle, a structure made of recirculating IgM+IgD+ B cells within a 
network of follicular dendritic cells (FDCs) (Figure 4). Here, B cells start to proliferate rapidly and 
push the IgM+IgD+ B cells aside to form the mantle zone around the GC, yielding a structure known as 
the secondary follicle. After a few days of vigorous proliferation, the characteristic structure of the GC 
becomes apparent (Figure 4): a dark zone consisting almost exclusively of densely packed 
proliferating B cells known as centroblasts, and a light zone comprised of smaller, non-dividing 
centrocytes situated within a mesh of FDCs, T cells and macrophages (Figure 4). Centroblasts 
diversify their IgV genes by SHM, and those cells that express newly generated modified antibodies 
are selected for improved antigen binding in the light zone. Some centrocytes eventually differentiate 
into memory B cells or plasma cells.  
 










The GC reaches its maximal size within approximately two weeks, after which the structure slowly 
involutes, and it disappears within several weeks. The formation of germinal centers is a complex 
process, which includes the interaction of several cell types within the germinal center environment as 
FDCs and TFH as well as a variety of transcription factors in activated B cells. Centroblasts express 
CXCR4 and migrate towards a CXCL12 gradient that originates in the light zone, whereas centrocytes 
express CXCR5, which is responsive to a CXCL13 gradient produced in the dark zone. Alternating 
upregulation and downregulation of the expression of these two chemokine receptors on GC B cells 
may promote the cycling of cells back and forth between the dark and light zones.(76) Nevertheless, a 
more recent study reveals that B cells tend to migrate along the dark-light zone border rather than to 
cross it.(140) A characteristic of centroblasts is their dramatically fast proliferation rate in the dark 
Figure 4: The germinal center microenvironment: Antigen-activated B cells differentiate into 
centroblasts that undergo clonal expansion in the dark zone of the germinal centre. During proliferation, 
somatic hypermutation (SHM) introduces base-pair changes into the V(D)J region of the rearranged genes 
encoding the immunoglobulin variable region (IgV) of the heavy chain and light chain; some of these 
base-pair mutations lead to a change in the amino-acid sequence. Centroblasts then differentiate into 
centrocytes and move to the light zone, where the modified antigen receptor, with help from immune 
helper cells including TFH cells and follicular dendritic cells (FDCs), is selected for improved binding to 
the immunizing antigen. Newly generated centrocytes that produce an unfavourable antibody undergo 
apoptosis and are removed. A subset of centrocytes undergoes immunoglobulin class-switch 
recombination (CSR). Cycling of centroblasts and centrocytes between dark and light zones seems to be 
mediated by a chemokine gradient of CXCL12 and CXCL13, presumably established by stromal cells in 
the respective zones (not shown). Antigen-selected centrocytes eventually differentiate into memory 
B cells or plasma cells. (from Klein et al. Nat. Rev Imm. 2008, 8:22-23) 
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zone of the germinal center.(141) The fast proliferation rate is required for the generation, within a 
short time frame, of large numbers of modified immunoglobulins, from which the few B cells that 
display antibodies with high antigen-binding affinity will be selected. Centroblasts upregulate genes 
associated with cell proliferation and downregulate genes encoding negative regulators of clonal 
expansion.(142,143) The physiology of dark zone centroblasts differs markedly from that of other 
proliferating cells in the body. Notably, the sensing of a response to DNA damage are specifically 
suppressed in centroblasts.(144) Furthermore, centroblasts express the enzyme telomerase (145), 
thereby ensuring that the vigorous clonal expansion of GC B cells does not result in a loss of their 
replicative potential, which would be a direct consequence of telomere shortening. GC B cells have 
long been known to be especially prone to apoptosis. Isolated GC B cells rapidly undergo apoptosis in 
vitro if they are not rescued by anti-apoptotic signals.(146) These findings indicate that the GC 
microenvironment provides crucial signals to GC B cells and decides their life and death. Centroblasts 
lack the expression of anti-apoptotic factors, including B cell lymphoma 2 (BCL-2) and its family 
members, whereas they express several pro-apoptotic molecules (133,142,147) (148), which allow the 
rapid execution of cell death by default or in response to exogenous signals. The major benefit of this 
pro-apoptotic nature of GC B cells is thought to be the rapid elimination of B cells with newly 
generated immunoglobulin mutations that produce a non-functional or non-binding antibody. This 
feature and the spatial concentration of proliferation, mutation and selection of antigen-activated 
B cells may have been the driving force for the evolution of the highly specialized GC structure. The 
transcription factor BCL6 is the master transcriptional regulator for centroblasts. BCL6 may allow GC 
B cells to sustain the physiological genotoxic stress that is associated with high proliferation, and 
sustain the DNA breaks that are induced by SHM and Class Switch Recombination (CSR). In addtion, 
BCL-6 inhibits the expression of genes involved in B cell activation during T cell-dependent immune 
responses, including CD69, CD80 and STAT1.(149) Interaction between CD80 on B cells and CD28 
on TFH cells in the light zone of the GC is essential for further differentiation towards memory B and 
plasma cells.(150)  BCL6 further inhibits differentiation of B cells into memory and plasma cells by 
suppressing transcription factors, like Blimp-1 which are required for final B cell differentiation. 
(149,151,152) Signalling through the B-cell receptor (BCR) leads to BCL6 ubiquitin-mediated 
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proteasomal degradation.(150) Signalling through CD40, which physiologically can be induced by 
T helper cells, results in the transcriptional silencing of BCL6 (153) through NF- B-mediated 
activation of IRF4.(154) Together, these mechanisms are likely to be crucial for the transition of GC 
B cells from centroblasts to centrocytes. Compared with centroblasts, centrocytes are very 
heterogeneous, perhaps consistent with the fact that they undergo diverse developmental fates, 
including the differentiation back into centroblasts and into post-GC cells: memory B cells or plasma 
cells. BCR stimulation coupled with co-stimulatory signals that are transmitted to the B cell by 
GC T cells provides survival signals to the cell. By contrast, failure of the BCR to bind antigen causes 
cell death. Recent evidence suggests that the differentiation of a GC B cell into a plasma cell is driven 
by the acquisition of a high-affinity BCR.(155) For memory B cells, the differentiation process instead 
seems to be stochastic, as throughout GC formation GC B cells are constantly selected to enter the 
memory pool.(156) During GC development, it is thought that CSR-inducing signals are transmitted to 
B cells by GC T cells that are present in the light zone. Recent studies demonstrated an important role 
for IRF4 in CSR. In Irf4-/- B cells, Aid mRNA and AID protein expression are not optimally induced, 
although IRF4 seems to regulate AID expression through intermediate molecules rather than through a 
direct mechanism.(157,158) In a subset of centrocytes induced to undergo CSR, IRF4 may be 
upregulated by the CD40–NF- B signalling pathway that is activated in these cells (159,160)  The fact 
that, in T-cell-dependent responses, class-switched cells are present among centroblasts as well as 
post-GC memory B cells and plasma cells suggests that the mechanism of CSR is activated in a 
distinct developmental window in the GC, and therefore not directly linked with the differentiation 
into a specific cell type.(161)  
Besides the requirement of signalling through the BCR in affinity-driven plasma-cell development 
(155), the signals that induce a GC B cell to differentiate into a plasma cell or a memory B cell are 
largely unknown. However, several transcription factors have been identified, of which the regulation 
is crucial for plasma-cell commitment.(162-164)  
IRF4 is one essential regulator of plasma-cell differentiation.(157,158) IRF4 has been suggested to act 
upstream of or in parallel to BLIMP1 for the generation of plasma cells. IRF4 also represses BCL6, 
thereby terminating the GC transcriptional programme.(154,158) Recent work suggest that the 
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expression of BLIMP1, IRF4 and XBP1 is independently regulated, but that the three transcription 
factors are jointly required for the establishment of the terminally differentiated plasma cells (165), as 
reflected by the dramatic effects of their individual deficiencies on plasma-cell development. 
(152,157,158) (166,167)   In contrast to the steps that lead to plasma cell differentiation, those that lead 
to the differentiation of a centrocyte into a memory B cell are less well characterized. Recent findings 
shed new light into our understanding of B cell memory formation and maintenance.(168) 
 
1.2.3 The role of germinal centers in B cell lymphomagenesis 
The GC response, which develops specific memory and plasma cells during the immune 
response against invading microorganisms, also comes with a risk. In fact, with the exception 
of the relatively rare lymphoblastic and mantle-cell lymphoma subtypes, most B-cell non-
Hodgkin lymphomas (B-NHL) display somatically mutated IgV genes, indicating that they 
are derived from B cells that are blocked within or have passed through the GC.(134,135) 
Gene-expression profiling has been used to define 3 molecular subtypes of diffuse large B cell 
lymphoma (DLBCL): i) germinal center B-cell-like (GCB) DLBCL; ii) activated B cell-like 
(ABC) DLBCL; iii) primary mediastinal B-cell lymphoma (PMBL). While GCL-DLBCL 
resembles germinal center B cells in the dark zone, ABC-DLBC resembles activated B cells 
during late germinal center reaction or postgerminal center B cells and is characterized by a 
constitutive activity of the NF-kB signaling pathway.(169,170) The mechansism underlying 
constitutive NF-kB activation in ABC-DLBCL are not completely understood yet, but recent 
findings have indicated that mutations in genes regulating NF-kB activity may induce its 
constitutive activation.(171,172) Nevertheless, in a large number of cases no mutations could 
be found and it remains to be determined whether the activation of the NF-kB signaling 
pathway, normally quiescent in centroblasts (143,159), may provide an ectopic survival signal 
to B cells or may reflect a particular developmental stage of the tumor-cell precursor 
(a centrocyte) that is subjected to signals that induce NF-kB activation. Among all DLBCL, 
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the ABC-DLBCL subtype represents the least curable. The third subypte, PMBL-DLBCL 
may derive from thymic B cells.(173,174)  
 
1.2.4 B cell lymphomas at nodal and extranodal site 
While the majority of DLBCL originate in lymph nodes, about 40% of all DLBCL present as 
extranodal tumors outside of secondary lymphoid organs.(175) Primary extranodal lymphoma is a 
disease confined to a single extranodal site, with or without regional lymph node involvement  The 
major sites of involment can vary but in general there is agreement that the gastrointestinal tract, 
Waldeyer`s ring, and skin make up the majority of primary extranodal lymphomas (176) Extranodal 
low-grade lymphomas of the marginal B-cell origine within mucosa-associated lymphoid tissue 
(MALT) in the stomach are associated with the presence of Helicobacter pylori.(177) In these cases, 
antibiotic treatment can lead to resolution of the lymphma in many but not all patients.(178,179) 
A similar relationship has been reported between ocular adnexal lymphoma and the presence of 
Chlamydia psittaci.(180,181) These findings highlight the importance of environmental stimuli for the 
generation and progression of some malignant lymphomas. In the last 20 years, a distinct increase of 
extranodal large cell lymphoma has been recognized in association with acquired immunodeficiency 
syndrome (AIDS) and intense immunosuppression following organ transplantation. In both 
cicumstances, extranodal presentation such as Primary Cenrtral Nervous System Lymphoma (PCNSL) 
was common and associated with Epstein-Barr virus (EBV).(182) It is therefore important to 
distinguish extranodal large cell lymphoma development in immunocompetent or 
immunocompromised patients (AIDS, post-transplantation). The site at which lymphoma cells 
proliferate is probably a reflection of an interaction between tumor cell characteristics (e.g. homing 
and adhesion molecules, growth factor receptors, etc.) and growth promoting microenvironmental 
features (presence of corresponding ligands and growth factors). Nevertheless, the crosstalk between 
malignant lymphocytes and its tumor microenvironment in extranodal lymphomas are poorly 
understood. A number of autoimmune diseases, e.g. rheumatoid arthritis and Wegener`s 
granulomatosis have been linked to an increased risk of NHL in general, an of primary extranodal 
INTRODUCTION                                                     B Cell Physiology and Lymphomagenesis 
 23 
NHL in particular.(183,184) Primary lymphoma of the thyroid has been often reported in patients with 
Hashimoto`s thyroiditis.(185) Of note, the primary organ of origin can influence the outcome. Two of 
the most unfavorable localizations of primary extranodal lymphomas are the CNS (PCNSL) and the 
testis (primary testicular NHL), which are both almost always from DLBCL subtype. The question, if 
malignant B cells are recruited to extranodal sites where they proliferate, or if malignant 
transformation takes place at extranodal site, remains to be resolved. The survial of patients with 
PCNSL only slightly increased over the last decades and a better understanding of the biology of this 
tumor is a major goal to improve patient`s outcome.  
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1.3 Primary Central Nervous System Lymphoma 
1.3.1 Incidence and epidemiology  
Primary central nervous system lymphoma (PCNSL) is a rare from of extranodal lymphoma which 
occurs in the brain, leptomeninges, spinal cord or eyes. Typically, it remains confined to the CNS and 
accounts for about 3% of primary brain tumors.(186,187)  Its incidence increased nearly 3-fold 
between 1973 and 1984 (188), but more recent data suggest that it may be stabilizing or declining 
slightlgy.(189) The only established risk factor is congenital (ataxia telangiectasia, Wiskott-Aldrich 
sydrome and severe common and combined variable immunodeficiencies) or acquired 
immunodeficiency (HIV infection, iatrogenic immune suppression). HIV-infected individuals with a 
CD4+ T cell count < 50cell / µl and a high peripheral viral load have a 3600-fold increased risk of 
developing PCNSL compared with healthy individuals (190) AIDS-related PCNSL are usually 
associated with EBV infection.(189) Since highly active antiretroviral therapy (HAART) has been 
introduced, the incidence of AIDS-related PCNSL has significantly declined.(191) Most cases of non-
AIDS related PCNSL are diagnosed in patients between 45 and 70 years of age, with a median age at 
diagnosis in the fifth decade.(192-195)  Men and women are equally affected.  
 
1.3.2 Clinical presentation and diagnosis 
PCNSL can manifest in the brain, its coverings, the eye or the spinal cord. Most cases of PCNSL 
present as symptoms related to the corresponding brain lesion. Symptoms at presentation include focal 
neurological deficits, neuropsychiatric symptoms, signs of raised intracranial pressure, seizures or 
ocular symptomes. In addition headaches, blurred vision, motor difficulties and personality changes 
(depression, apathy, psychosis, confusion, visual hallucinations) can occur depending on the 
infiltration of the tumor. In addition to a detailed history and physical examination, the evaluation of 
patients suspected of having PCNSL should include imaging of the CNS with contrast-enhancing 
magnetic resonance imaging (MRI), cerebrospinal fluid (CSF) analysis and slit lamp examination of 
both eyes. Fifty to seventy percent of immunocompetent patients with PCNSL develop solitary 
lesions, the remaining 25 percent developing multifocal brain lesions. Periventricular lesions 
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(thalamus, basal ganglia and corpus callsoum) are most common followed by lesions in the frontal, 
parietal, temporal and occipital lobes. Although mild surrounding edema is present in the majority of 
cases, it is usually less profound than accompanying metastatic foci of carcinoma. Evaluation of the 
cerebrospinal fluid (CSF) may reveal the presence of malignant lymphoid cells in up to 30 percent of 
patients with PCNSL. The CSF often reveals an elevated protein concentration and a lymphocytic 
predominant pleocytosis. The demonstration of neoplastic lymphocytes in CSF is sufficient to confirm 
the diagnosis of PCNSL and obviates the need for a brain biopsy. However, while a positive CSF 
analysis can provide valuable diagnostic informations, negative results do not exclude PCNSL. The 
diagnostic procedure of choice to confirm PCNSL is a stereotactic needle biopsy, followed by 
immunohistochemical analysis.(196) The pathologic evaluation and classification of PCNSL is similar 
to that of tumors of systemic non-Hodgkin lymphoma. Tumors are evaluatied based upon their 
morphology and immunophenotype. The vast majority of PCNSL are of the aggressive or highly 
aggressive, diffuse large B cell subtypes from an activated B-cell-like phenotype (ABC-
DLBCL).(197) A histopathological feature of PCNSL is the angiocentric behaviour of malignant 
B cells. Malignant B cells tend to infiltrate along the perivascular spaces building up a concentric 
circle of densely packed blasts around small and intermediate size vessels. PCNSL often contain 
mixtures of tumor cells, reactive astrocytes and infiltrating T lymphocytes. Reactive perivascular 
T cell infiltrates (RPVI) are found in about half of PCNSL cases and their presence is associated with 
better overall survival compared to RPVI-negative PCNSL cases.(198) It remains elusive, whether the 
immune system can recognize PCNSL and elicit antitumor effector function, or whether infiltrating 
lymphocytes are tolerogenic. T cell subsets in PCNSL have not been analyzed up to date and the role 
of tumor infiltrating lymphocytes in the progression or suppression of PCNSL remains to be 
determined. In addition, crosstalk mechanisms between bystander cells like activated microglia or 
infiltrating lymphocytes and malignant B cells in PCNSL have not been studied. Signals from the 
tumor environment may provide tumor promoting or tumor suppressing signals to malignant B cells in 
PCNSL. Several attempts to isolate and culture PCNSL-derived malignant B cells have failed. Similar 
to B cells isolated from germinal centers, PCNSL B cells rapidly undergo apoptosis in vitro, indicating 
that PCNSL cells may depend on signals provided by the tumor environment. Blocking signals 
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between malignant cells and its environment may therefore have important clinical implications and 
may improve therapeutic intervention and patients’ outcome. 
 
1.3.3 Pathogenesis 
1.3.3.1 Cellular origin of PCNSL 
The cellular and molecular events leading to neoplastic lymphocytic infiltration of the CNS seen in 
PCNSL are not well understood.(199) It has been suggested that clonal proliferation may occur among 
normal B lymphocytes drawn to the CNS, a theory that is supported by the occurrence of white matter 
brain lesions that precede brain lymphoma.(200) The observation that systemic dissemination of 
PCNSL only occurs rarely suggests that the cell of origin may be derived from neoplastic lymphocytes 
that are eradicated from the periphery by an intact immune system, but which are able to traffic and 
survive in an immunological privileged site, such as the CNS.(193,201-203) In several PCNSL 
patients, B cell clones have been identified in the bone marrrow which share BCR rearrangement with 
the malignant B cell clone in the CNS (204), indicating, that lymphoma cells in the CNS may have a 
growth advantage, while circulating lymphoma cells lack specific survival signals in the 
microenvironment or may be recognized and deleted by the immune system. Several adhesion 
molecules including CD44 have been implicated in the interaction between lymphoma cells and tumor 
endothelial cells.(205,206) CNS tropism may be facilitated through the expression of specific cell-
surface adhesion molecules or chemokine receptors on malignant B cells. Malignant B cells in PCNSL 
have been reported to express the chemokine receptors CXCR4, CXCR5 and CCR7 (108) showing a 
phenotype resembling activated B cells during late germinal center reaction. In addition several 
homeostatic chemokines have been described in PCNSL (203,207) and in CSF from PCNSL 
patients.(208)  
 
1.3.3.2. Molecular features 
The increased incidence of PCNSL in immunodefiecient individuals strongly implicates the immune 
system in the pathogensis of PCNSL. In fact, in immunocompromised patients, EBV may have a 
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causal link to the development of PCNSL (209,210) In contrast, the majority of immunocompetent 
patients do not appear to have EBV genomic DNA within their tumors. PCNSLs show clonal 
rearrangement in their IgHV genes and high levles of somatic hypermutation (SHM) of 
immunoglobulin genes and intraclonal heterogeneity (211-214), pointing towards their derivation from 
late germinal center B cells. Complementary DNA expression profiling experiments support the 
existence of similar molecular subtypes for PCNSL and systemic DLBCL, including germinal center 
B-cell-type (GCB) and activated B-cell-type (ABC) expression profiles.(170,215) The vast majority of 
PCNSL have an ABC-DLBCL phenotype (197) sharing molecular characteristics of late germinal 
center B cells such as the expression of the transcription factor IRF4 but not the plasma cell marker 
CD138.(197) However, Rubenstein at al. reported an overlapping state of differentiation in malignant 
B cells in PCNSL, characterized by expression of both GCB and ABC genes.(216) Aberrant SHM 
targeting the regulatory or coding regions of proto-oncogenes such as c-MYC, PIM1, RhoH/TTF and 
PAX5 has been described in both systemic lymphoma and PCNSL.(217,218)  It is therefore tempting 
to think of PCNSL and systemic DLBCL as disorders reflecting faulty class-switch recombination or 
SHM.(219) 
 
1.3.3.3. The role of infectious agents 
Infectious agents promote lymphomagenesis through direct transforming properties or sustained 
antigenic stimulation. EBV genomic material is identified in over 90% of PCNSL tissue from 
immunocompromised patients.(220) EBV episomes are not found in PCNSL occurring in 
immunocompetent patients, and the notion that EBV might still be involved in B cell oncogenesis in 
this population remains speculative. Intriguingly, it has been shown that EBV infection of B cells 
results in expression of AID and polymerase η, both of which are crucial enzymes for SHM. Aberrant 
SHM involving growth-regulatory genes might provide B cells with a survival advantage independent 
from EBV infection.(221)  Another important mechanism of pathogenesis in systemic lymphoma is 
chronic antigenic stimulation. Relatively strong evidence for this mechanism exists for Borrelia 
Burgdorferi-associated cutaneous marginal zone lymphoma and Helicobacter Pylori-related gastric 
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mucosa-associated lymphoid tissue lymphoma (MALT) as well as ocular adnexal lymphoma and the 
presence of Chlamydia psittaci.(180,181) 
 
1.3.4 Therapeutic intervention 
Treatment options for immunocompetent patients with newly diagnosed PCNSL include 
corticosteroids, radiation therapy, and chemotherapy. A stereotactic biopsy is indicated for all patients 
with suspected PCNSL. The administration of corticosteroids should be withheld prior to biopsy to 
avoid diagnostic inaccuracy. PCNSL patients relapse quickly when treated exclusively with 
corticosteroids and always require additional therapy. Whole brain radiation therapy (WBRT) is often 
deferred in PCNSL patients older than 60 years in complete remission after primary chemotherapy. 
The administration of chemotherapy regimens that are effective for extracranial aggressive 
lymphomas (i. e. CHOP regimen) showed poor results in PCNSL patients, (222,223) probably due to 
limited penetration of the chemotherapeutic drug through the blood-brain barrier (BBB). The most 
effective drug against PCNSL is high-dose Methotrexate (HD-MTX).(224-227) Several drugs with 
potential BBB penetrating properties have been added to HD-MTX and are currently tested in clinics. 
Preliminary results from a few trials in relapsed patients are available with temoxolomide, topotecan, 
rituximab and the PCV regimen (228-231) Chemotherapy alone has been emphasized to minimize 
radiation-related neurotoxicity, especially in elderly patients. With chemotherapy alone, durable 
responses are possible, although most patients experience relapse. Additional intrathecal MTX 
administration to the HD-MTX treatment demonstrated no survival benefit.(232) The vast majority of 
PCNSL patients will experience tumor relapse or progression and will requrie salvage therapy. The 
precise mechanism that leads to treatment resistance in PCNSL is not well understood. It has been 
hypothesized that promoter methylation of the reduced folate carrier (RFC) gene is responsible for 
MTX resistance.(233) The five year overall survival remains poor and is between 40–
70 %.(226,227,234) To improve the prognosis of patients with PCNSL a better understanding of the 
biological mechanisms of this tumor is therefore necessary.   
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1.4 The Role of the Microenvironment in Malignancies 
1.4.1 The inflammatory environment in malignancies  
Oncogenic processes are typically viewed independently of the immune response against the tumor. 
The hallmarks of cancer include tumour-cell proliferation and survival, tumour angiogenesis and 
metastasis.(235) The activation of proto-oncogenes and oncogenic signalling pathways together with 
inactivation of tumour-suppressor genes in cancer cells are crucial processes in malignant 
transformation and progression.(235-237) At the same time, tumor immunologists have uncovered 
many cellular and molecular mechanisms that mediate tumor escape from natural immune 
surveillance, which functions as an extrinsic tumor suppressor.(238-240) The paucity of 
immunological danger signals necessary for immune activation, the increased concentration of 
immunosuppressive factors, and the accumulation of immunosuppressive cells in the tumor 
microenvironment indicate that immune regulation has an active role in cancer progression.  
An inflammatory component is present in the microenvironment of most neoplastic tissues, including 
those not causally related to an obvious inflammatory process. Hallmarks of cancer-associated 
inflammation include the infiltration of white blood cells, the presence cytokines and chemokines and 
the occurrence of tissue remodeling and angiogenesis.  
Strong evidence suggests that cancer-associated inflammation promotes tumor growth and 
progression.(239,241,242) Previous studies have shown that a high frequency of tumor-associated 
macrophages (TAMs) was linked with poor prognosis.(243,244) Interestingly, this pathological 
finding has reemerged in the postgenomic era: genes associated with leukocyte or macrophage 
infiltration (e.g. CD68) are part of the molecular signatures associated with poor prognosis in different 
malignancies.(243,245) In recent years, TAMs have been divided into M1 and M2 type according to 
their antitumoral or protumoral cytokine profiles.  Classically M1 macrophages can exert cytotoxic 
activity on tumor cells and elicit tumor-destructive reactions. In contrast M2 macrophages express 
several protumoral functions, including promotion of angiogenesis, matrix remodelling and 
suppression of adaptive immunity.(246-248) TAMs can exert dual functions on malignant cells (the 
macrophage balance hypothesis) (246), and can negatively affect the activation of antigen-specific 
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CD4+ T cells.(249) Signal transducer and activator of transcription 3 (STAT3) is a transcriptional 
factor activated by a number of cytokines that seem to be situated at the crossroads of multiple 
oncogenic signalling pathways. It is constititutively activated in tumor and immune cells of the tumor 
microenvironment, thus contributing to the regulation of the cell composition and role of the immune 
infiltrate.(250) In fact, macrophages with STAT3 activity are thought to play an important role in the 
crosstalk between tumor cells and their immunological microenvironment, leading to tumor-induced 
immunosuppression. Consequently, they have been proposed as being a potential target for cancer 
immunotherapy.(251)   
Tumor infiltrating CD4+ and CD8+ T cells are likely to be important in achieving immunological 
control of tumors.(252-256) While CD8+ T cells are believed to kill malignant cells, CD4+ T cells have 
a role in the activation of CD8+ cytotoxic T cells. CD8+ T cells are potent effectors of the adaptive 
antitumour immune response. The target antigens that are recognized by tumour-reactive CD8+ T cells 
have been shown to be mostly non-mutated self-antigens that are also expressed by tumour 
cells.(257,258)  Tumour-specific CD4+ T cells have been also identified, but their functionality can be 
manifold because CD4+ T cells can help or hinder anti-tumour immune responses.(259,260)  
Regulatory T cells (T regs) are crucial for the maintenance of peripheral self-tolerance and for the 
suppression of antitumor responses.(261)  T reg cells represent a unique T cell lineage that is 
characterized by expression of the transcription factor forkhead box P3 (FOXP3) and high levels of 
expression of cell-surface molecules associated with T cell activation. By releasing 
immunosuppressive cytokines such as IL-10 and TGF β, regulatory T cells, which are over-
represented in tumor lesions from patients with melanoma and lung cancer, can inhibit the function of 
infiltrating T cells.(262,263) The presence and the suppressinve effects of T reg cells might therefore 
contribute to the poor clinical outcome of certain types of malignancies.  
 
1.4.2 The tumor microenvironment in B cell malignancies 
Development and progression of B cell malignancies are driven by a combination of cell intrinsic 
events and cell extrinsic events. Cell intrinsic events, such as oncogene activation or tumor-suppressor 
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gene inactivation lead to increased proliferative activity or decreased apoptosis.(264) Lymphoid 
neoplasms are characterized by well-defined chromosomal translocations and by the accumulation of 
subsequent molecular alterations involving mainly the cell cycle and/or apoptotic pathways. However, 
ex vivo culture of isolated malignant B cells is limited and is an indicator, that their survival in vivo is 
also dependent on cell extrinsic signals from accompanying cells in the microenvironment.(265)  
Signals in the tumor environment can reach malignant B cells via cell-cell interactions or via soluble 
factors. In chronic lymphocyte leukemia, cell-cell interactions via CD40/CD40L between CLL and 
T cells cooperate with BCR signalling to trigger survival of tumor B cells.(266,267) In addition, 
survival of CLL cells in vivo (268) and in vitro.(269) have been associated to increased  B cell survival 
factors, such as BAFF and APRIL  BCR transmits survival and death signals throughout B cell 
development and abnormal BCR stimlulation provides constitutive signalling for the survival of 
B lymphoma cells.(270,271) These findings indicate that environmental signals strongly influence the 
behaviour and survival of malignant B cells. Uncontrolled tumor growth leads to mass effects and 
elicit inflammatory responses.  Immune responses in malignant lymphomas can be manifold 
depending on the recruitment of different immune effectors.  
The presence of Tregs for instance has been shown to be associated with different clinical oucomes, 
depending on their location, number and tumor context.(272-275) In epithelial derived cancers, the 
presence of Tregs generally correlates with poor clinical prognosis.(262,263)  In contrast, high numbers 
of Tregs in follicular lymphomas are associated with improved overall survival and small numbers of 
Tregs is associated with transformation to DLBCL.(273) Tumor-infiltrating lymphocytes in Hodgkin 
lymphoma are enriched in Treg cells, which create an immunosuppressive environment that explains 
the lack of an effective anti-tumor response.(276) Differences in clinical outcome between lymphoid 
malignancies and epithelial malignancies have also been described in terms of CD8+ T cells. While in 
various tumors, the presence of CD8+ T lymphocytes correlate with better prognosis, conflicting 
results have been reported in B cell malignancies. In Hodgkin lymphoma CD8+ T cells represent a 
small proportion of the T cell infiltrate and their presence in the tissue is a marker for unfavourable 
prognosis associated with shorter progression-free survival.(277,278) Beside different adaptive 
immune effectors, innate immune effectors also seem to play an important role in the clinical outcome 
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of B cell malignancies. Tumor-associated macrophages with increased STAT1 activity and 
immunosuppressive capacity have been found in some lymphomas, especially surrounding tumor cells 
in Hodgkin lymphomas and follicular lymphomas, where they have been associated with an 
unfavourable prognosis.(277,279,280) A classical example of tumor-cell survival dependent on the 
presence of environmental factors are B cell malignancies associated with microbial or viral 
pathogens.  Several lines of evidence support the hypothesis that chronic antigenic stimulus can 
promote and sustain the growth of MALT-type marginal zone B cells in the stomach, fist causing 
acute and chronic gastritis, and subsequently gastic lymphoma.(281) Detailed analysis of the crosstalk 
between malignant B cells and their microenvironment will provide the basis for the development of 
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2. THE STUDY  
2.1 Aim of the study 
The germinal center is the main source of memory B cells and plasma cell generation. They produce 
high affinity antibodies, which are necessary to protect us against invading microorganisms. However, 
the beneficial role of GC B cells in immunity is somewhat counterbalanced by their detrimental role in 
lymphomagenesis, as the majority of B-cell lymphomas originate from GC B cells. Germinal center 
B cells express a distinct set of chemokine receptors such as CXCR4, CXCR5 and CCR7, which 
regulate their migration and positioning during and after germinal center reaction. Similar to 
centrocytes and centroblasts, malignant B cells derived from germinal centers can retain a particular 
set of chemokine receptors which allow them to respond to their cognate ligands expressed in the 
microenvironment. Investigation of B cell attracting chemokines within and outside germinal centers 
may not only improve our understanding of B cell trafficking within secondary lymphoid organs, but 
also help understanding tumor cell distribution and dissemination of malignant B cells derived from 
germinal centers.  
The germinal center microenvironment is essential for survival of B cells. It is therefore tempting to 
hypothesize, that GC-derived B cell malignancies may at least partly depend on survival signals from 
their microenvironment. This hypothesis is corroborated by the fact, that malignant B cells from 
DLBCL quickly undergo apoptosis in vitro. Special emphasis should therefore be given to bystander 
cells in DLBCL and their effects on malignant B cells.   
PCNSL remains a poorly understood and often fatal DLBCL confined to the CNS. Malignant B cells 
in PCNSL resemble late germinal center B cells and express classical B cell chemokine receptors, 
such as CXCR4, CXCR5 and CCR7. The present work was focusing on B cell attracting chemokines 
in the microenvironment of PCNSL, with the aim of improving our understanding on PCNSL 
microenvironment, including type, density and localization of tumor infiltrating lymphocytes and the 
potential role of specific chemokines in their recruitment. Detailed analysis of the crosstalk between 
normal and malignant B cells with their chemokine environment may provide insights on the strict 
organ tropism shown by malignant B cells.  
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The presented project includes four major sections: 
I. Analysis of the expression of B cell attracting chemokines under normal and 
inflammatory conditions in human secondary lymphoid organs.  
II. Analysis of  T and B cell attracting chemokines in extranodal CNS lymphomas 
III. Analysis of  type, density and localization of tumor infiltrating lymphocytes in 
PCNSL  
IV. Analysis of the effect of coexpressed chemokines in PCNSL on the migratory 
responses of tumor-infiltrating lymphocytes and malignant B cells.  
 
2.2 Strenght of the study 
PCNSL is a rare and often fatal CNS tumor. Thanks to the collaboration with one of the most 
important European center for the study and management of patients with PCNSL, we had at our 
disposal samples from 22 patients. Due to the fact that animal models for PCNSL are not jet available, 
these samples represent a unique collection for assessing both tumour cell characteristics and tumour 
microenvironment.   
In the majority of malignancies, tumor cells are surrounded by a heterogenous population of bystander 
cells that contribute to tumor progression. To better understand the tumour characteristics is therefore 
important to strictly distinguish between tumor-derived factors and microenvironment-derived factors. 
Gene expression studies on malignant B cell lymphomas are often performed without prior separation 
of malignant B cells and bystander cells, resulting in the analysis of genes, which are upregulated in 
the microenvironment rather than in the tumor cells. A way of bypassing this issue is detailed 
histomorphological analysis or cell separation prior to analysis. Cell separation methods generally lead 
to a significant loss of cells during processing and require large patient samples. We therefore focused 
on detailed histomorphologic analysis of various proteins and their mRNA expression. Our work 
provides new findings in the crosstalk between malignant B cells and its microenvironment and 
improves our understanding of cellular dynamics within PCSNL. The strict organ tropism of PCNSL 
may at least partly be explained by our findings, supporting a model, where the inflammatory CNS 
response creates a niche-like environment, in which malignant B cells find optimal conditions for 
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further proliferation and progression.  The data provided here may also be valid for a variety of other 
malignancies or chronic inflammatory conditions, such as multiple sclerosis. It emphasizes the 
importance of inflammatory bystander cells in releasing homing/trapping or survival signals to normal 
and malignant cells.     
 
2.3 Limitations of the study 
Biomedical research on human tissue samples is indispensable for improving our understanding of 
physiology and pathology in human diseases. Nevertheless, scientific investigation on human samples 
often remains restricted due to well defined ethical constraints and limited accessibility of human 
tissue. In immunology and tumor biology, murine models have developed as powerful tools to 
investigate health and model diseases. PCNSL are rare extranodal lymphomas restricted to the CNS 
and our understanging of the pathophysiology of this B cell lymphoma remains very limited. The 
difficult accessibility, the lack of appropriate animal models and the inability to maintain malignant 
B cells from PCNSL in culture challenges our scientific investigation. Clinical and radiological 
investigation, stereotactic biopsy, immunohistopathological analysis and chemotherapeutic treatment 
are standard procedures for patients with PCNSL. To perform functional assays, such as migration and 
killing assays isolation of malignant B as well as tumor-infiltrating T cells from patient`s samples 
would be required. Unfortunately, we did not have access to fresh tissue samples, which would have 
allowed us to perform these experiments. Therefore this study remains mainly based on description, 
while proof of principle experiments are missing. While recent gene expression profiles of PCNSL 
added important information, they analyzed total tumor mRNA and therefore neglect the cellular 
heterogeneity within PCNSL consisting of  malignant B cells, infiltrating immune effectors and 
resident bystander cells such as activated microglia.  Despite being partially descriptive, this work 
adds important value to our understanding on the interaction between the tumor microenvironment and 
tumor cells, and encourages future studies on the crosstalk between organ specific resident cells and 
proliferating malignant B cells. 
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3. MATERIAL AND METHODS  
Material and methods regarding the manuscripts are listed there. This section includes only material 
and methods not listed in the manuscript.  
 
Tissue specimens  
Normal resting human lymph nodes from different localizations (inguinal, iliac, mesenteric, 
pulmonary) were received from human organ donors.  Samples were fixed in 10% buffered formalin 
and embedded in paraffin. Sections from reactive lymph nodes were from patients that underwent 
lymphadenectomy due to chronic lymphadenopathy. Histopathological analysis showed absence of 
hematologic malignancies and samples were considered as reactive, inflammatory lymph nodes. 
Sections were received from the Department of Pathology, Scientific Institute of San Raffaele, Milan, 
Italy. Human tonsils were from patients undergoing tonsillectomy due to chronic tonsillitis. Samples 
were fixed in 10% buffered formalin and embedded in paraffin. Paraffin-embedded tissue was cut in 
sections of 4-5µm thickness and analyzed by immunohistochemistry, in situ hybridization or 
immunofluorescence microscopy.  
Antibodies  
Rabbit anti-human CD3 (RM-9107) was purchased from Thermo Scientific (Cheshire, UK) and used 
for immunostaining at 1:50. Mouse anti-human CD8 (M7103), CD20cy (M0755), CD68 (M0876), 
Smooth muscle actin (SMA) (M0851) and Cytokeratin (M0821) were purchased from DAKO 
(Glostrup, Denmark) and used at concentrations following manufacturer`s recommendations. Mouse 
anti-human CXCL12 (MAB350) was purchased from R&D Systems (Abingdon, UK) and used for 
immunostaining at 5 µg/ml. Goat anti-human CXCL9 (AF392), CCL21 (AF366) and CXCL13 
(AF801) were purchased from R&D Systems, and used at 1 µg/ml, 1 µg/ml and 2 µg/ml. Rat anti-
mouse PNAd (550564) was purchased from PharMingen and used at 2.5 µg/ml. 
Immunostaining  
Immunostaining was performed by initial deparaffinization and rehydration of tissue sections. Slides 
were boiled at 95°C for 30 minutes in target retrieval solution (S1699, DAKO Cytomation). Tissue 
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slides were treated with Peroxidase Blocking Reagent (S2001, DAKO) and Protein Block Serum-Free 
(X0909, DAKO). As negative controls for immunostainings, nonrelated isotype-matched 
immunoglobulins were used.  Primary antibodies were diluted in Antibody Diluent (S3022, DAKO). 
Sections were then incubated overnight at room temperature in a humid chamber, followed by 
incubation with the appropriate secondary antibodies: rabbit anti-mouse Ig/biotinylated/F(ab`)2 
(E0413, DAKO) or rabbit anti-goat Ig/biotinylated (0466 DAKO) diluted 1:200 in Antibody Diluent 
(S3022, DAKO) for 30 minutes at room temperature. Slides were washed and incubated with 
StreptABComplex/ Horseradish peroxidase (HRP) (K0377, DAKO). After washing, sections were 
developed with 3-amino-9-ethylcarbazole (A-6926, Sigma-Aldrich, Buchs, CH), washed in water and 
counterstained with Hematoxylin. Immunofluorescence stainings were performed following the same 
protocol used for immunohistochemistry. Fluorescence-labelled secondary antibodies purchased form 
Molecular Probes (Invitrogen, Carlsbad, CA, USA) were as follows: goat anti-mouse IgG1 Alexa 
Fluor 488 (A-21121) and 594 (A-21125), goat anti-rat IgG Alexa 594 (A-11007), goat anti-mouse 
IgG2a Alexa Fluor 594 (A-21135), goat anti-mouse IgG3 Alexa Fluor 488 (A-21151), goat anti-rabbit 
IgG Alexa Fluor 488 (A11070), rabbit anti-goat IgG Alexa Fluor 594 (A-11080). Appropriate 
secondary antibodies were diluted 1:400. After washes, slides were mounted in 4,6 diamidino-2-
phenylindole (DAPI)-containing mounting medium (H-1200, Vectashield, Vector Laboratories, 
Burlingame, CA, USA). 
In situ hybridization  
35S-labeled sense and antisense for CCL21mRNA probes, 310 bp in length and corresponding to 
position -59 to -368 bp of CCL21 sequence (NM002989),  CXCL13mRNA probes, 355 bp in length 
and corresponding to position -35 to -364 bp of CXCL13 sequence (NM006419) CXCL12mRNA 
probes, 236 bp in length and corresponding to position -111 to -346 bp of CXCL12 sequence 
(NM199168) and CXCL9 mRNA probes, 372 bp in length and corresponding to position -46 to -
417bp of the CXCL9 sequence (NM002416), probes were generated by in vitro transcription (10 999 
644 001, Roche, Rotkreuz, CH). Tissue sections were kept under RNAse free conditions during the 
whole procedure. After dewaxing and rehydrating the slides in graded ethanol solutions, in situ 
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hybridization was performed, according to a previously described method.(24) Finally, the sections 
were dipped in Kodak photo emulsion NTB-2 (Rochester, NY) and exposed in complete darkness for 
14 days at 4°C. Development and fixation were performed according to the instructions provided by 
Kodak, and counterstaining was performed with hematoxylin.  
Image analysis 
Immunohistochemical and in situ hybridization staining were analyzed with Nikon Eclipse E800 light 
microscope. Digital pictures were acquired with a Nikon Digital Camera DXM1200, and Act-1 
software (Nikon AG, Egg, CH). Digital image analysis for CXCL9 mRNA expression was performed 
with Nikon NIS-Elements BR 2,10. Immunofluorescence stainings were analyzed with a Nikon 
Eclipse E800. Image acquisitions were performed with Hamamatsu EM-CCD Digital camera C9100 
and Openlab 5,5 software (Improvision, Coventry, UK). Lymphocyte distribution was assessed by 
quantitative analysis of cell per high power field (HPF), counting 10-20 different areas within each 
sample at 400x magnification.  
Statistical analysis 
Statistical analsysis was performed with GraphPad Prism 4 using Mann Whitney test. 
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4. RESULTS  
4.1 B cell attracting chemokines in human secondary lymphoid organs 
4.1.1 B cell attracting chemokines in normal human secondary lymphoid organs 
During their lifetime, B cells express various chemokine receptors. The two classical chemokine 
receptors of B cells are CXCR4 and CXCR5.  Depending on their developmental and activation state, 
they can also express CCR7 and CXCR3. While ligands for these receptors have been extensively 
studied in murine secondary lymphoid organs under homeostatic and inflammatory conditions, their 
expression under homeostatic and inflammatory conditions in humans is less well studied.  To 
improve our understanding of lymphocyte trafficking in human secondary lymphoid organs under 
normal and inflammatory conditions, we focused on the expression of their appropriate ligands 
CXCL12 (CXCR4), CXCL13 (CXCR5), CCL21 (CCR7), and the three CXCR3-ligands CXCL9, 
CXCL10 and CXCL11. We performed immunohistochemical analysis for the abovementioned 
chemokines in resting and inflamed secondary lymphoid organs received from organ donors, patients 
undergoing tonsillectomy or lymphadenectomy. Sense and antisense probes have been generated for 
CXCL12, CXCL13 and CCL21 and in situ hybridization has been performed on resting lymph nodes 
from organ donors. The analysis showed three distinct expression patterns for CCL21, CXCL13 and 
CXCL12 in normal resting lymph nodes (Figure 5).  
 
Figure 5: mRNA expression 
of chemokines in normal 
resting human lymph nodes.  
In situ hybridization for 
CCL21, CXCL13 and 
CXCL12 in normal resting 
inguinal lymph node. CCL21 
expression is restricted to 
parafollicular T cell areas and 
is absent in B cell follicles 
(left panels). CXCL13 
expression is mainly restricted 
to B cell follicles underlying 
the subcapsular sinus 
(intermediate panels). 
CXCL12 expression is most prominent along subcapsular, intermediate and medullary sinuses (right panels). 
Representative results are shown. Images show signal intensity with antisense probes, sense probes showed no 
signal. (Magnification 60x in top panels, and 125x in bottom panels). 
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Consistent with previous reports in mouse (282), CXCL13 was mainly confined to the B cell follicles 
underlying subcapsular sinuses in normal lymph nodes, while CCL21 was completely absent in B cell 
follicles, but was present in high concentration in the parafollicular T cell area.(26) Under homeostatic 
conditions, CXCL12 expression was most prominent along subcapsular, intermediate and medullary 
sinuses within resting lymph nodes. Similar to CCL21mRNA, CXCL12mRNA was also present in the 
T area, but could not been detected in B cell follicles (Figure 5). Immunohistochemical stainings for 
the CXCR3-ligands CXCL9, CXCL10 and CXCL11 showed no positive staining in normal resting 
lymph nodes. 
To confirm translation of chemokine mRNA into proteins, we analyzed expression of CCL21, 
CXCL13 and CXCL12 by immunohistochemistry. We found similar reticular expression pattern of 
CCL21 and CXCL12 in the T area, consistent with stromal compartments (51) CCL21, CXCL13 and 
CXCL12 protein expression showed complementary pattern compared to mRNA expression (Figure 
6) indicating that immunohistochemical stainings with the antibodies detect specifically the 
appropriate chemokines. CCL21 showed expression within the T area and around HEVs (Figure 6A). 
CXCL13 stained follicular dendritic cells in primary B cell follicles (Figure 6B). Strong expression of 
CXCL12mRNA in the subcapsular, indermediate and medullary sinuses could also be confirmed by its 
protein expression (Figure 6C).  
 
 
Figure 6:  chemokine protein expression reflects mRNA expression in normal resting lymph nodes 
(A) Images show CCL21 protein expression (top panel) and CCL21mRNA expression (bottom panel) in the 
T cell area. The image shows a reticular expression pattern with close association to HEV. (B) CXCL13 protein 
(upper panel) and mRNA (lower panel) expression in primary B cell follicles. (C) CXCL12 protein (upper 
panels) and mRNA (lower panels) expression in the subcapsular, intermediate and medullary sinuses 
(Magnification  100x). 
RESULTS                                                         B cell attractants in secondary lymphoid organs 
 41 
Slight differences between protein and mRNA expression were detected on HEVs. While HEVs 
showed positivity for CXCL12 expression, no mRNA was detected, indicating a chemokine transport 
from the abluminal T cell compartment towards the luminal side of HEVs (Figure 7B). CCL21mRNA 
and protein was detected in close proximity to HEVs. Nevertheless, no direct overlay with CXCL12 
was found on HEVs (Figure 7A/C). In contrast, CCL21 and CXCL12 colocalized in the parafollicular 
T area (Figure 7C).  
 
Figure 7: Expression of CCL21 and CXCL12 in T cell areas and on HEVs in normal resting lymph nodes 
(A) Immunhistochemical (top panel) and in situ hybridization (bottom panel) for CCL21. Images show T cell 
areas including HEVs (B) Immunhistochemical (top panel) and in situ hybridization (bottom panel) for 
CXCL12. Images show T cell areas including HEVs (C) Double immunofluorescence stainings for CCL21 and 
CXCL12 in T cell areas (upper panels, Magnification 800x) and HEVs (lower panels, Magnification 400x) 
arrows indicate HEVs. Representative images are shown. 
 
 
In resting human lymph nodes, the B cell attractant chemokine CXCL13 mainly localizes in B cell 
follicles underlying the subcapsular sinus (Figure 6B). Cells with long dendrites can also be found in 
close proximity the subcapsular sinuses (Figure 6B, upper panel). 
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4.1.2 Inflammation-induced changes of chemokine expression 
We further investigated inflammation-induced changes of homeostatic B cell attracting chemokines in 
secondary lymphoid organs. Chemokine expression in inflamed human tonsils and reactive lymph 
nodes was analyzed and the expression pattern was compared to normal lymph nodes. In contrast to 
normal resting lymph nodes, inflamed secondary lymphoid tissue classically presents with germinal 
center formation. As summarized in the introduction, germinal center formation is a complex process 
of subsequent events which requires B cell and plasma cell migration at several time points. In 
humans, these migration steps are poorly understood. To improve our understanding of B cell 
trafficking within and outside of germinal centers, we analyzed the expression pattern of CCL21, 
CXCL12, CXCL13 and CXCL9.  
Under inflammatory conditions, immunostainings for the CCR7-ligand CCL21, showed a similar 
expression pattern compared to resting secondary lymphoid organs. CCL21 protein and mRNA was 
mainly confined to the parafollicular T area and in close proximity to HEVs (Figure 8). The germinal 
centers as well as the mantle zone were negative for CCL21 (Figure 8). While downregulation of 
CCL21mRNA expression has been described under several acute inflammatory conditions in the 
mouse (283,284), we have not detected major differences in CCL21mRNA expression between 
normal and chronically inflamed secondary lymphoid organs.  
 
 
Figure 8: CCL21 expression in 
chronically inflamed secondary 
lymphoid organs. 
Immunhistochemical and in situ 
hybridization for CCL21 in 
chronically inflamed human 
tonsils. Germinal centers are 
polarized towards the tonsillar 
crypt. GC and tonsillar crypt is 
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We further investigated the expression of CXCL12 in inflamed secondary lymphoid organs. Inflamed 
tonsils showed positive staining in three distinct areas: 1) in the tonsillar crypt 2) within germinal 
centers and 3) in T cell areas (Figure 9).  
 
Figure 9: CXCL12 expression in tonsillar crypt, germinal centers and T cell areas of inflamed secondary 
lymphoid organs. Immunohistochemical staining for CXCL12 in inflamed human tonsils show expression in 
the tonsillar crypt (i), within the germinal center (ii) and in the T cell area (iii). 
 
Similar as in resting lymph nodes, CXCL12 is found on PNAd+ HEVs in parafollicular areas of human 
inflamed tonsils and reactive lymph nodes and did not colocalized on smooth muscle actin positive 
(SMA+) pericytes (Figure 10D). Interestingly perivascular accumulation of CD20+ B cells around 
HEVs in the T cell area is commonly found in human secondary lymphoid organs (Figure 10B). This 
phenomenon has also been reported in murine lymph nodes.(126)  
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Figure 10: Perivascular accumulation of B cells around CXCL12+ HEVs in parafollicular T areas.  Double 
immunofluorescence microscopy of inflamed human tonsil for CXCL12 and CD20, PNAd and SMA.  (A) T area 
with CXCL12+ HEVs between 2 germinal centers. White circles indicate B cell distribution around HEVs in the 
T area (Magnification 100x). (B) High magnification of a CXCL12+ HEV in the T area with perivascular B cell 
distribution (Magnification 800x) Double staining with PNAd (C) (Magnification 800x) and SMA (D) 
(Magnification 600x) confirm its expression on HEVs SMA: smooth muscle actin, PNAd: peripheral node 
addressin.  
 
CXCL12 expression within the B cell follicles changed under inflammatory conditions. While in B 
cell follicles of normal lymph nodes, follicular CD68+ marcophages do not show CXCL12 expression, 
highly phagocytic tingible body macrophages (TBM) in germinal centers showed strong CXCL12 
staining in inflamed tonsils as well as reactive lymph nodes (Figure 11). In contrast to FDCs, TBMs 
are equally distributed within the germinal center and are positive for the macrophage marker 
macrosialin (CD68) (Figure 11). TBMs engulf apoptotic germinal center B cells which fail to develop 
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further towards memory B or plasma cells. They can regulate germinal center reactions.(133,285) and 
decreased phagocytic activity of TBMs in the germinal center can lead to autoimmunity.(286) In 
contrast to previous reports in the mouse (76), we did not detect an obvious gradient of CXCL12 
between the light and dark zone of the germinal center.  
Interestingly, strongest expression of CXCL12 in normal and inflamed secondary lymphoid organs 
was found at the sites, where antigen encounter occurs. This includes the subcapsular sinuses in lymph 
nodes (Figure 5 and 6) and the crypt epithelium of inflamed tonsils (Figure 9).  
 
Figure 11: CXCL12 expression in the germinal center Double immunofluorescence microscopy on normal 
(Mag 200x), reactive (Mag 100x) and tonsillar (Mag 100x) secondary lymphoid tissues for CXCL12 and the 
macrophage marker macrosialin (CD68). 
 
 
Crypt-derived CXCL12 in the tonsil is produced by cytokeratin positive epithelial cells. This network 
of CXCL12-expressing epithelial mainly harbors CD20+ B cells (Figure 12). A considerable amount 
of plasma cells is also present within this meshwork, while only a few T cells are present in the crypt 
(data not shown).  
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Figure 12: Tonsillar crypt cells build a CXCL12-expressing reticular network filled with B cells.  
Double immunofluoresence microscopy of inflamed human tonsils stained with CXC12, the epithelial marker 
Cytokeratin (upper panels, Magnification 400x) or the B cell marker CD20 (bottom panels, Magnification 100x). 
Images show network of tonsillar crypt epithelial cells interspersed by CD20+ B cells. Crypt epithelium stains 
strongly positive for CXCL12.   
 
In inflamed secondary lymphoid tissue, CXCL13 expression is mainly confined to areas within the 
germinal center. In germinal centers, CXCL13 shows a polarized expression patter and is found 
exclusively in the light zone of the germinal center and the adjacent mantle zone (Figure 13).The 
highest density of CXCL13+ cells occurs at the border between the germinal center light zone and the 
adjacent mantle zone (Figure 13).  
 
Figure 13: CXCL13 expression in primary 
and secondary B cell follicles in secondary 
lymphoid organs Immunohistochemical 
staining for CXCL13 in resting (LN) and 
inflamed (tonsil) secondary lymphoid organs. 
Upper panels show CXCL13 expression in 
resting lymph node in B cell areas underlying 
the subcapsular sinus. The expression pattern 
is mainly reticular and cells show long 
dedrites which can reach the subcasular 
sinus. Bottom panels show CXCL13 
expression in the germinal center light zone 
and the mantle zone of inflamed tonsils. The 
strongest staining occurs on the edges 
between light zone and mantle zone. 
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CXCL13+ cells in the light zone of GCs represent a fraction of CD3+ TFH cells as well as CD3- FDCs 
(Figure14). Interestingly the majority of CD3+ follicular T cells are negative for CXCL13, indicating 
either functional heterogeneity between TFH cells or upregulation of CXCL13 at a special time point 
within the germinal center reaction (Figure14). CXCL13+ TFH cells are enriched in close proximity to 
the germinal center border between light zone and mantle zone (Figure14). CD3+ T cells outside the 
germinal center and mantle zone are negative for CXCL13 (Figure 14).   
 
Figure 14: CXCL13 expression in the germinal center (A) Double immunofluorescence microscopy of 
representative germinal center in inflamed tonsil for CXCL13 and CD3. Yellow color indicates CXCL13+CD3+ 
TFH cells. Red color only stains FDCs (Magnification 100x) (B) CXCL13+ CD3- FDC (left panel) and 
CXCL13+ CD3+ TFH cells (right panel) in the germinal center light zone (upper panels, magnification 800x). 
Inset shows accumulation of CXCL13+ TFH cells on the edge of the germinal center between light zone and 
mantle zone (bottom panel) (Magnification 400x). 
 
CXCL9, CXCL10 and CXCL11, ligands for the chemokine receptor CXCR3, could only been 
detected in secondary lymphoid organs under inflammatory conditions. While CXCL10 and CXCL11 
expression was restricted to a few cells (data not shown), CXCL9 expression showed a T cell area-
restricted expression pattern. Protein and mRNA for CXCL9 were found in dinstinct interfollicular 
clusters and showed a reticular expression pattern, whereas germinal centers showed no CXCL9 
expression (Figure 15). CXCL9+ cells show a dendritic-cell-like morphology (Figure 15).  
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Figure 15.  In situ hybridization and 
immuno-histochemistry for CXCL9 in 
inflamed secondary lymphoid organs. 
T area-restricted mRNA expression of 
CXCL9 in the parafollicular areas of 
inflamed tonsils (upper panels). Insets show 
CXCL9-expressing cells in the T area with 






CXCR3, the receptor for CXCL9 is typically expressed on CD8+ T cells and may therefore play and 
important role in the tissue distribution of CD8+ T cells in the T area of inflamed secondary lymphoid 
organs. Indeed, tonsillar CD8+ T cells accumulate in areas with high CXCL9 expression (Figure 16).  
While the vast majority of CD8+ T cells are found in the T area outside germinal centers, a few CD8+ 
T cells are also present within germinal centers (Figure 16A). In contrast to CD4+ follicular T cells, 
which accumulate only in the germinal center light zone, CD8+ follicular T cells seem to be equally 
distributed in the germinal centers or accumulate in small CD8+ T cells clusters.  






staining for CXCL9 (left 
panel) and CD8 (right 
panel) on consecutive 
slides in inflamed human 
tonsil show 
complementary images. 
(B) Graph showing CD8+ 
T cell accumulation in T 
cell areas with CXCL9 
expression. Cell were 
counted in high power 
fields in at least 10 
different GC or areas 
with or without CXCL9 
expression (C) Double 
immunofluorescence 
microscopy for CXCL9 and CD8 shows accumulation of CD8+ T cells in CXCL9+ area (Magnification 125x 
upper panels, 800x bottom panels).  
 
RESULTS                                                                                         B cell attractants in PCNSL 
 49 
4.2 T and B cell attracting chemokines in PCNSL 
4.2.1 Patients 
To investigate whether there are parallels between the B cell attractant chemokine environment in 
secondary lymphoid organs and extranodal DLBCL confined to the CNS, we performed a 
retrospective study on samples from 22 patients with PCNSL. Table 3 summerizes patients`s 
characteristics and the extension of disease. Brain specimens were taken for diagnosis of B cell 
PCNSL between 2001 and 2005, from 11 men and 11 women, aged 35 to 75 years (median 65 years). 
All patients were immunocompetent, HIV negative, and Epstein-Barr virus encoded RNAs (EBER) 
negative. Diagnosis of PCNSL by immunophenotyping and routine hematoxylin and eosin staining 
was used to characterize the tumors according to the current World Health Organization (WHO) 
classification. No patient selected for this study received an antitumor treatment (neither 
chemotherapy nor radiotherapy) before surgical biopsy. All patients received corticosteroids before 
biopsy to control symptoms by reducing brain edema and tumor mass effect. Steroids were interrupted 
10-15 days before biopsy to reduce the interfering effect of these drugs on histopathological features. 
Table 3. Patients’ characteristics and extension of disease. 
Patients(n= 22) 
Age median 65 
 range 35-75 
 age >70 ys. 7/22 (32%) 
Males 11/22 (50%) 
ECOG-PS 0 - 1 12/22 (55%) 
 2 - 3 10/22 (45%) 
Histotype α Diffuse large B-cell lymphoma 21/22 (95%) 
 Burkitt-like lymphoma 1/22 (  5%) 
Systemic symptoms 0/22 (  0%) 
LDH ratio >1 3/17 (18%) 
Ocular diseaseβ 0/11 (  0%) 
Positive CSF cytology examination β 1/10 (10%) 
High CSF protein level β 3/11 (27%) 
Multiple lesions 10/22 (45%) 
Involvement of deep structures χ 10/22 (45%) 
 
α
 Histotype was defined according to the WHO Classification. 
β
 Relationship between the number of positive cases and the total number of assessed patients.  
χ
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4.2.2 CXCL12 expression in PCNSL 
In most of the PCNSL cases, malignant B cells remain confined to the CNS. It is therefore tempting to 
hypothesize that the CNS microenvironment releases factors, which favor CNS restriction. CXCL12 is 
well known as a key player for the retention of HSC, B cell precursors and plasma cells in the bone 
marrow.(63,64,67-71,74,75)  Previous reports have shown, that malignant B cells in PCNSL resemble 
late germinal center B cells and uniformly express CXCR4.(108,197) We therefore investigated in 
detail the expression pattern of its ligands CXCL12 in samples from PCNSL patients. In line with a 
previous report (207), we detected strong expression of CXCL12 in all 22 PCNSL cases (22/22). Yet, 
our findings indicated, that the source of CXCL12 in all analyzed cases was the inflammatory tumor 
microenvironment, rather than the malignant B cells themselves. Similar to our findings in the 
germinal center (Figure 11), CXCL12 in PCNSL was mainly restricted to CD68+ 
microglia/macrophages with large cytoplasm or dendritic cell-morphology as well as endothelial cells 
(Figure 18A/B). Tumor associated macrophages in PCNSL show large phagocytic morphology, 
similar to tingible body macrophages within germinal centers (Figure 17A). High numbers of CD68+ 
macrophages were found in all investigated PCNSL cases. Their density of TAMs in PCNSL was 
comparable with the density of TBM within germinal centers (Figure 17B).  
 
Figure 17. Morphology and distribution of 
macrophages in PCNSL and germinal 
centers Immunohistochemical stainings for 
CD68 in PCNSL cases and germinal centers. 
(A) Representative images for tumor associated 
macrophage (TAM) distribution in PCNSL (left 
panels) and tingible body macrophages (TBM) 
in germinal centers (B) Graph showing average 
numbers of TBMs and TAMs in germinal 
centers and PCNSL cases respectively. CD68+ 
macrophages were counted in high power fields 
(Magnification 800x) in 10 cases of PCNSL and 
20 germinal centers. 
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Figure 18:  CXCL12 expression in PCNSL microenvironment. (A) Immunohistochemical staining for 
CXCL12 in 3 representative cases of PCNSL show CXCL12 positivity in large cells with big cytoplasm and 
small nuclei as well as on small and intermediate size vessels (black arrows). Double immunofluorescence 
microscopy for CXCL12 and CD68+ microglia/macrophages in the tumor microenvironment (B) (Magnification 
200x) and CD20+ malignant B cells (C) (Magagnification 400x). (D) and (E) show stainings as in (B) and (C) in 
the germinal center of inflamed human tonsils (Magnification 800 and 300x, respectively).  
 
To improve our understanding of tumor infiltration and distribution within the CNS, we analyzed in 
more detail CXCL12 distribution and the presence of CD20+ malignant B cells at the tumor border 
from 3 out of 22 cases, where peritumoral CNS tissue was present. As expected, we found that in 
peritumoral areas, elongated cells show CXCL12 expression in the absence of CD20+ malignant 
B cells (Figure 19A ii). CXCL12 expressing cells decreased with increasing distance to the tumor 
border (Figure 18). These findings indicate that peritumoral microglial cells may sense alterations in 
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Figure 19: CXCL12 
expression at the tumor 
border of PCNSL. 
(A) Immuno-histochemical 
analysis of CXCL12 
expression (brown) at the 
tumor border of PCNSL 
cases. Black line in the large 
image indicates tumor border. 
PCNSL (upper right corner) 
and adjacent cerebellar tissue. 
Insets are marked and 
represent i) intratumoral, 
ii) peritumoral and iii) extra-
tumoral areas. Larger 
magnifications of insets are 
shown on the right. 
Immunofluorescense stainings 
for CD20 and CXCL12 
indicates malignant B cell 
distribution on the tumor edge 
with elongated CXCL12+ cells 
(green) in the peritumoral area 
in the absence of CD20+ 
malignant B cells 
(Magnification 300x)  
(B) Images show tumor 
border in two additional 
PCNSL cases where 
malignant B cells are 
infiltrating CNS tissue. CXCL12 is found in the tumor microenvironment. Tumor mass is on the bottom left, 





4.2.3 CXCL13 expression in PCNSL 
Beside CXCR4, malignant B cells in PCNSL express CXCR5.(108) Its ligand CXCL13 has been 
reported to be upregulated in PCNSL.(203,287) By morphological analysis part of these cells 
producing CXCL13 has been ascribed to B cell blasts, whereas the analysis of gene expression profile, 
performed later, could not specifically focus on the CXCL13 producing cells. We performed 
additional immunhistochemical and immunofluorescence stainings for CXCL13 alone and in 
combination with CD20 and CD68. In line with previous reports, we found upregulation of CXCL13 
in all PCNSL analyzed. In addition to the previus data, we have observed CXCL13 staining in CD68+ 
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macrophages/microglia, as well as on a fraction of tumor infiltrating CD3+ T cells (Figure 20). These 
findings indicate that malignant B cells in PCNSL are embedded in an inflammatory environment of 
activated microglia/macrophages, which in addition release B cell attractant chemokines. 
 
Figure 20: CXCL13 expression 
in the PCNSL 
microenvironment . 
(A)  Immuno-histochemical 
stainings for two representative 
cases of PCNSL stained with 
CXCL13. Positive staining is 
found on a fraction of cells (black 
arrows). 
Double immunofluorescence 
microscopy for CXCL13, CD68 
and CD3 in PCNSL shows overlay 
with CD68+  microglia/ 
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Novelty and impact of the paper 
 
This study addresses the hierarchy of the distinct co-expression of B and T cell attractant chemokines 
in the tumor microenvironment which control cell trafficking of both tumor infiltrating lymphocytes 
and malignant B cells and improves our understanding of cellular dynamics within PCNSL. 
Therapies targeting chemokine interactions between malignant cells and its microenvironment might 
disrupt tumor-supporting interactions and improve anti-tumor immunity.  
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Abstract 
Primary central nervous system lymphomas (PCNSL) are aggressive malignancies confined to the 
CNS, mostly of diffuse large B cell histotype. Despite improved understanding of the malignant 
B cells, little is known on the tumor microenvironment and on the response of the adaptive immunity 
against PCNSL. We investigated the phenotype of tumor infiltrating lymphocytes (TILs), and the 
expression of chemokines that could affect malignant B cells and trafficking of TILs.  
TILs and chemokine expression were evaluated by immunohistochemistry and in situ hybridization. 
Furthermore, we performed in vitro migration assays to analyze the migratory capacity of lymphocytes 
and malignant B cells towards chemokines and chemokine heterocomplexes.      
We show in 22 cases of PCNSL from immunocompetent patients that CD8+ T cells represent the 
majority of TILs in the tumor mass. They tend to accumulate in perivascular areas, show Granzyme B 
expression, and proliferate in situ. Their localization and density correlates with the expression of the 
inflammatory chemokine CXCL9, which is transcribed and translated by perivascular macrophages 
and pericytes in the perivascular microenvironment. Moreover, CXCL9 and CXCL12 are coexpressed 
on the tumor vasculature and form heterocomplexes. In the presence of CXCL9, CXCL12-induced 
migration is enhanced not only on CXCR4+/CXCR3+/CD8+ T cells but also on CXCR4+/CXCR3- 
malignant B cells.  
These findings indicate the presence of a strong chemoattractant stimulus in the perivascular 
microenvironment, which might serve as regulator for the recruitment of TILs and for the angiocentric 
positioning of malignant B cells in the perivascular cuff.  
 
Introduction 
Primary central nervous system lymphomas (PCNSL) are aggressive malignancies confined to the 
central nervous system (CNS), mostly of diffuse large B cell histotype. It counts for about 5% of 
primary CNS tumors and its incidence augmented significantly over the last three decades.1,2 Despite 
improved therapeutic intervention, the prognosis of PCNSL remains poor. The majority of previous 
studies on PCNSL focused on the phenotype of malignant B cells, and only recent findings indicate a 
potential role of the microenvironment.3 Moreover, recent studies in various tumors highlight the 
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importance of the environment for neoplastic development and progression.4 Type, density, and 
location of different tumor infiltrating lymphocytes (TILs) influence clinical outcome due to the 
recruitment of T cell subsets that provide tumor-suppressive or tumor-promoting stimuli.5 To improve 
our knowledge on the tumor pathophysiology it is therefore essential to investigate the T cell subsets 
that are attracted to the tumor, and the chemotactic stimuli which regulate their recruitment.6-8 
Unlike most other organs, the CNS is an immunoprivileged site with restricted access and unique 
microenvironment that profoundly affects the capacity of T cells to enter and exert their functions.9 
Lymphocyte recruitment is regulated by the chemokine receptors expressed on their surface and by 
selective chemokines expressed in tissues. In addition, the chemokine receptor profile of malignant 
B cells allows their migration towards chemotactic cues in the tumor microenvironment. Perivascular 
T cells and accumulation of malignant B cell around vessels are commonly found in PCNSL.10 This 
histological characteristic may be initiated and sustained by distinct molecules, including T and B cell 
attracting chemokines. We show that the CXC chemokine ligand (CXCL) 9, agonist of the CXC 
chemokine receptor (CXCR) 3, is expressed in the perivascular area and that TILs accumulate in areas 
with high CXCL9 expression. In addition, CXCL9 forms heterocomplexes with the B cell 
chemoattractant CXCL12, expressed on the tumor vasculature, and enhances CXCL12-induced 
migration on malignant B cells.  
The perivascular microenvironment in PCNSL can therefore regulate the recruitment of specific T 
cell subsets to the tumor and modulate the migratory behavior of both TILs and malignant B cells 
within the tissue. 
 
Materials and Methods 
Patients and tissues 
Brain specimens were taken for diagnosis of B-cell PCNSL (2001-2005), from 11 men and 
11 women, aged 35 to 75 years (median 65 years). All patients were immunocompetent, HIV negative, 
and Epstein-Barr virus encoded RNAs (EBER) negative. Diagnosis of PCNSL by 
immunophenotyping and routine hematoxylin and eosin staining was used to characterize the tumors 
according to the current World Health Organization (WHO) classification. Corticosteroid regimen was 
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stopped 10-15 days prior to biopsy. Initial screening for CXCR3, CXCR3-ligands and the CCL21 was 
performed on micro-tissue arrays on 20 cases.  
 
Immunostaining procedures 
Tissue sections from formalin-fixed, paraffin-embedded blocks were used for 
immunohistochemical and immunofluorescence stainings as previously described 11 using antibodies 
against cellular markers as described below.  
Rabbit anti-human CD3 (RM-9107) and mouse-anti human CD57 (MS-136-P0) were from Thermo 
Scientific (Cheshire, UK) and used at 1:50 and 2 µg/ml, respectively. Mouse anti-human CD4 (Clone 
4B12) was from Novocastra (Newcastle, UK) and used at 1:100. CD8 (M7103), CD20cy (M0755), 
CD68 (M0876) Granzyme B (M7235), Interferon regulatory factor 4 (IRF4) (M7259), Smooth muscle 
actin (SMA) (M0851) and rabbit anti-human Ki-67 (A0047) were from DAKO (Glostrup, Denmark) 
and used for immunostaining at 4.6 µg/ml, 7 µg/ml, 0.6 µg/ml, 1.1 µg/ml, 4.8 µg/ml, 6 µg/ml, and 
5.5 µg/ml, respectively. Mouse anti-human Forkhead box P3 (Foxp3) (CM299A) was from BioCare 
Medical (Concord, USA) and used at 1:100. Mouse anti-human CXCL12 (MAB350) and CXCR3 
(MAB160) were from R&D Systems (Abingdon, UK) and used for immunostaining at 5 µg/ml and 
2 µg/ml, respectively. Anti-human CXCR3-PE (557185), CXCR4-APC (555976) were from BD 
Biosciences (Belgium), and used for cytofluorimetric analysis at 1:50. Anti-human CC chemokine 
receptor (CCR) 1 (MAB145), CCR5 (MAB182), CCR7 (MAB197), CXCR3 (MAB160), CXCR4 
(MAB173) and CXCR5 (MAB190), CXCL9 (AF392), CXCL13 (AF801) were from R&D Systems 
used at 1 µg/ml.  
Secondary antibodies were used according to manufacture instructions: rabbit anti-mouse 
Ig/biotinylated/F(ab`)2 (E0413, DAKO), rabbit anti-goat Ig/biotinylated (0466 DAKO), goat anti-
mouse Ig/RPE (R0480, DAKO), goat anti-mouse IgG1/ Alexa Fluor 488 (A-21121, Invitrogen, 
Carlsbad, CA, USA), goat anti-mouse IgG2a Alexa Fluor 594 (A-21135, Invitrogen), goat anti-rabbit 
IgG Alexa Fluor 488 (A11070, Invitrogen), rabbit anti-goat IgG Alexa Fluor 594 (A-11080, 
Invitrogen). 
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In situ hybridization 
35S-labeled sense and antisense CXCL9 mRNA probes, 372 bp in length and corresponding to 
position -46 to -417bp of the CXCL9 sequence (NM002416), were generated by in vitro transcription 





Immunohistochemical, immunofluorescence, and in situ hybridization stainings were analyzed 
with Nikon Eclipse E800 microscope. Digital pictures were acquired with a Nikon Digital Camera 
DXM1200, and Act-1 software (Nikon AG, Egg, CH), or with Hamamatsu EM-CCD Digital camera 
C9100 and Openlab 5,5 software (Improvision, Coventry, UK). Lymphocyte infiltration was assessed 
by quantitative analysis of cells in all PCNSL cases, counting 3 different areas within each tumor 
sample at 400x magnification. CXCL9 mRNA expression was quantified by digital image analysis 
(NIS-Elements BR 2.10) on the whole tumor area and expressed as percentage.  
 
Chemokine synthesis 
All chemokines were chemically synthesized using tBoc solid-phase chemistry.14 All chemokines 
were tested for full length and homogeneity by mass spectrometry.  
Co-Immunoprecipitation 
Immunoprecipitation of CXCL12 and CXCL9 at 200nM was performed using chemically 
synthesized chemokines. CXCL9 alone or in combination with CXCL12 was incubated for 30 min at 
37°C in RPMI containing 0.5% BSA and protease inhibitors (Sigma Aldrich P8340, 1:1000). 
Chemokine solutions were then incubated at 4°C overnight with 2.5 µg/ml anti-CXCL9 (R&D, 
MAB392) and for additional 2h with 5 µg/ml biotinylated rabbit anti-mouse antibody (DAKO, 
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Cells 
PBMC were isolated from buffy coats of donor blood (Central Laboratory of the Swiss Red 
Cross, Basel, Switzerland) by Ficoll-Paque density centrifugation. CD8+ T lymphocytes were isolated 
by a positive immunoselection procedure (CD8 MicroBeads, Miltenyi Biotec, Bergisch Gladbach, 
Germany), and cultured for 24 h before chemotaxis assays as previously described.15 DLBCL cell 
lines (OCI-Ly7, OCI-Ly10, OCI-Ly19, SU-HDL6) from different DLBCL subtypes (Activated B-
Cell-like and Germinal Center B-Cell-like) 16 were kindly provided by Dr. Eric Davis, National 
Cancer Institute, NIH, Bethesda, MD, USA, analyzed for different surface molecules (Supplementary 
Fig. S2), and used for migration assays.  
 
Chemotaxis assays 
Chemotaxis was assayed in 48-well Boyden microchambers (Neuro Probe, Cabin John, MD) as 
previously described.17 Cells migrated to the lower sides of the filters were counted at 1000x 
magnification in 5 high-power fields.  
 
Statistical analysis 




Lymphocyte infiltration, distribution, and activation state in PCNSL 
Immunohistochemical analysis for CD8, CD4, and Foxp3 expression in 22 PCNSL cases revealed 
that CD8+ and CD4+ lymphocytes are selectively recruited to the tumor mass (Fig. 1A). This 
observation was corroborated by the analysis of five cases with enough peritumoral tissue to allow 
quantification of CD8+ T cells both within the tumor and in the surrounding tissue (Fig. 1C). In most 
cases, intratumoral CD8+ T cells were the prominent subset, followed by CD4+ cells (Fig. 1B). In 
contrast, Foxp3+ lymphocytes were rarely observed (Fig. 1A-B). TILs, and in particular CD8+ T cells, 
showed a predominant accumulation in perivascular areas within the tumor mass (Fig. 1A and 1D). 
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To further characterize the CD8+ T cell subset, we analyzed the presence of Granzyme B, an 
indicator of cytotoxic activity, and Ki67, an indicator of cell proliferation. Approximately half of the 
intratumoral CD8+ T cells were positive for Granzyme B with a typical polarized pattern directed 
towards the target cells (Fig. 2A, left panels). Up to 15% of intratumoral CD8+ T cells were Ki67+ 
(Fig. 2A, right panels).  
CXCL13+ follicular dendritic cells (FDCs) 12,13 and follicular B helper T cells (TFH) are present in 
normal germinal centers (Supplementary Fig. S1). TFH cells consist of an heterogeneous population 
that have been shown to provide help to the B cells, by inducing activation-induced cytidine 
deaminase (AID) and promoting survival of germinal center B cells 18-20. Of note, the tumor cells in 
PCNSL resemble late germinal center B cells 21 and produce CXCL13 11 that might also be responsible 
for the recruitment of TFH lymphocytes. Indeed, we found that a fraction of CD3+ TILs produces 
CXCL13 and expresses CD57 (Fig. 2B), comparable to TFH cells present in the germinal center of 
human tonsil (Supplementary Fig. S1).  
The transcription factor interferon regulatory factor 4 (IRF4) is upregulated in T lymphocytes 
after T cell receptor stimulation, and plays a critical role for the differentiation of naïve to Th2 or Th17 
effector lymphocytes 22,23. IRF4 is also upregulated during late germinal center B cell differentiation 
and its expression has been shown in PCNSL 24,25. In the human tonsil, CD3+IRF4+ lymphocytes are 
mainly restricted to the light zone of the germinal center and are in close proximity to IRF4high light 
zone germinal center B cells (Supplementary Fig. S1). In PCNSL, malignant B cells as well as around 
10% of the TILs show IRF4 expression (Fig. 2B) suggesting TCR-mediated activation.  
These findings indicate that different subsets of adaptive immune effectors are recruited to 
PCNSL. A fraction of intratumoral CD8+ T cells show an activated phenotype with cytotoxic and 
proliferative activity. The recruitment or induction of TFH-like T cells may provide tumor promoting 
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Perivascular CXCL9 expression in the PCNSL microenvironment 
The abundance of TILs led us to investigate the expression of chemotactic cytokines which may 
regulate CD8+ and CD4+ T lymphocyte recruitment. Beside CCR7, which is expressed on naïve and 
central memory CD4+ and CD8+ T cells 26, CXCR3 and CXCR4 are expressed on all CD8+ 
T lymphocyte subsets and on activated CD4+ lymphocytes.27,28 Immunohistochemical analysis for the 
agonists of CCR7 (CCL21), CXCR3 (CXCL9, CXCL10, and CXCL11), and CXCR4 (CXCL12) 
showed high expression of CXCL9 (Fig. 3) and CXCL12 in all the investigated cases, whereas 
CXCL10, CXCL11 and CCL21 were undetectable (data not shown). While CXCL9 and CXCL12 
showed similar expression pattern in the vascular and perivascular area, CXCL12 showed in addition a 
broad distribution within the tumor microenvironment, as previously shown by other groups.29,30 To 
further investigate the expression profile of CXCL9, we generated antisense and sense probes for the 
detection of CXCL9 mRNA and performed in situ hybridization on all 22 cases. CXCL9 mRNA 
colocalized with the protein detected by immunohistochemistry, confirming its production in situ 
(Fig. 3A). This chemokine, produced in the perivascular environment, can be additionally transported 
to the luminal surface of endothelium, as it has been shown for inflammatory chemokines 31. Double 
immunofluorescence stainings reveal the perivascular microenvironment (SMA+ and CD68+) as the 
major source of CXCL9 (Fig. 3C). In contrast, malignant B cells, which have been shown to produce 
CXCL13 11, do not seem to contribute to CXCL9 production. The percentage of CXCL9+ area within 
the tumor mass was calculated in all cases by digital image analysis and ranged from 0.5% to 55%. 
Tumor samples were divided according to their CXCL9 mRNA expression into 3 subgroups: i) low 
(0.5-5 %), ii) intermediate (>5-20 %), or iii) high (> 20%) CXCL9 expression (Fig. 4A), and further 
analyzed. 
 
T cell infiltration correlates with CXCL9 expression in PCNS 
The amount of CXCL9 in each PCNSL sample was compared to the number of TILs (as from 
Fig. 1B). Samples with intermediate and high CXCL9 expression showed significantly higher CD8+ 
T cell infiltration than the ones with low CXCL9 expression (Fig. 4B, top panel). Similar differences, 
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although less prominent, were found between expression of CXCL9 and the presence of CD4+ or 
Foxp3+ T cells (Fig. 4B, middle and bottom panels).  
The distinct perivascular expression of CXCL9 and the distribution of CD8+ TILs prompted us to 
quantify, on consecutive slides from five different patients, CD8+ lymphocytes accumulating in areas 
with high CXCL9 expression (Fig. 4C). The analysis showed that CD8+ lymphocytes preferentially 
accumulate in areas with CXCL9 expression (Fig. 4D). These findings strengthen the role of CXCL9 
as important factor for the recruitment of adaptive immune effectors into the perivascular area. 
 
CXCL9 forms heterocomplexes with CXCL12 and enhances CXCL12-induced migration of CD8+ 
T cells and malignant B cells  
Reactive perivascular T cell infiltrates and angiocentric behavior of malignant B cells represent 
one of the histological characteristics of PCNSL. T lymphocytes form an inner circle, and malignant 
B cells an outer concentric circle of densely packed cells in the perivascular sheet 10 (Fig. 5A-B). In 
line with previous reports we found that CXCL12 is expressed in PCNSL microenvironment (Fig. 5B, 
right panels).29,30 Here we show that, both CXCL9 and CXCL12, are present on endothelial cells 
(Fig. 5B-C), 
Our group and others reported that inflammatory chemokines can synergize, by forming 
heterocomplexes, to induce stronger responses to homeostatic chemokine receptor agonists 15,32,33. 
Indeed, we show that also CXCL9 and CXCL12 form heterocomplexes in solution (Fig. 5D). We 
therefore investigated the potential role of CXCL9 as enhancer of CXCL12-induced migration of 
CD8+ T cells and malignant B cells.  
To investigate the effect of these chemokines on circulating CD8+ T cells, we performed in vitro 
migration assays on cells from healthy individuals. Circulating CD8+ T cells express CXCR4, as well 
as CXCR3 and respond to both CXCL12 and CXCL9 (Fig. 6A). When CXCR3+/CXCR4+/CD8+ 
T cells are incubated simultaneously with CXCL9 and CXCL12 at any chemokine concentration, the 
effect on cell migration is additive, indicating increased capacity to migrate towards areas where these 
chemokines are coexpressed (Fig. 6B).  
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To investigate the effects of CXCL9 and CXCL12 on malignant B cells, we used four different 
DLBCL cell lines, tested for phenotypic markers including chemokine receptors (Supplementary 
Fig. S2). Their chemokine receptor profiles were in line with previous studies in PCNSL.29,34 None of 
the investigated DLBCL cell lines expressed CXCR3, the selective receptor for CXCL9, or responded 
to CXCL9 (Supplementary Fig. S2, and Fig 6C), whereas they efficiently migrated at 100 nM 
CXCL12 (migrated cells/5 high power fields: OCI-Ly10 249.8±27.1, OCI-Ly7 293.7±29.4, OCI-Ly19 
107.1±6.3, SU-HDL6 277.7±23.1 and Fig.6C). Interestingly, only in the presence of CXCL9 all four 
cell lines efficiently migrated at sub-optimal concentration of CXCL12 (10 nM) (Fig. 6D), indicating 
synergistic activity between CXCL9 and CXCL12 on CXCR4. This synergistic activity was observed 
in all DLBCL cell lines regardless their subtype (Fig. 6D).    
 
To further investigate the chemokine requirements for inducing synergism with CXCL12, we 
performed the same migration assays in the presence of CCL4. Synergistically acting chemokines 
have been shown to feature polar and /or basic residues in the first β-strand 32, which results in patch 
of low electronegativity in the respective location of the chemokine surface. While CXCL9 fulfils 
these criteria, CCL4 has two acidic residues in the first β-strand, and consequently high 
electronegativity in the respective surface area. Moreover, it is an agonist for CCR1 and CCR5, both 
of them absent on DLBCL cell lines (Supplementary Fig. S2). In contrast to CXCL9, CCL4 lacked 
synergistic activity on CXCL12-induced migration (data not shown) suggesting specific structure 
requirements for CXCL12 synergy-inducing chemokines.  
Our findings show that CXCL9 expressed in perivascular areas can form heterocomplexes with 
CXCL12 and in this way enhances CXCR4-dependent migration of malignant B cells towards the 
vessel wall. Furthermore, CXCL9 and CXCL12 cooperate acting on their selective receptors to recruit 
CXCR3+/CXCR4+/CD8+ T cells. The data presented support a model in which the pattern of 
chemokine expression in the perivascular area regulates the recruitment of adaptive immune effectors 
and might explain the angiocentric positioning of malignant B cells in PCNSL. 
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Discussion 
This study focuses for the first time on T cell subsets present in the microenvironment of PCNSL, 
and analyzes the co-expression of chemokines that might regulate TILs infiltration and malignant 
B cell positioning. The finding that the majority of TILs are CD8+ T cells which express Granzyme B 
and proliferate in situ indicates TCR-mediated recognition, activation-induced proliferation, and 
cytotoxic activity. Nevertheless, PCNSL have a poor prognosis and the immune response might not be 
sufficient to appropriately counterbalance tumor growth. Inefficient migration of cytotoxic TILs 
within the tumor may be one of the mechanisms leading to tumor evasion. In addition other factors, 
including in situ released cytokines such as Transforming Growth Factor β (TGFβ) 35 may profoundly 
decrease the cytotoxic activity of CD8+ TILs. A fraction of TILs share phenotypic markers of TFH cells 
present in the light zone of germinal centers, such as CXCL13 and CD57, and show IRF4 expression 
indicating TCR-mediated activation and differentiation towards Th2 or Th17.22,23,36 Interestingly, a 
recent report highlighted the importance of Th2 cell help for the development of lymphomas in a 
mouse model.37 Those large B cell lymphomas are also IRF4+, as PCNSL 24, and developed 
consistently at extranodal sites.37 The fraction of TILs with a TFH phenotype, which are present in 
PCNSL, might provide costimulatory and antiapoptotic signals to malignant B cells, similar to the 
activity of TFH cells on the B cells present in the light zone of the germinal centers 38. It remains to be 
determined, whether malignant proliferating B cells educate their environment to produce soluble 
factors or upregulate costimulatory signals on infiltrating T cells, to build up a germinal center-like 
environment. The CXCL13+ T cells could also correspond to a T cell subset recently described in 
rheumatoid arthritis39 or to Th17 lymphocytes.40  
Functional studies on TILs and malignant B cells derived from PCNSL are impractical due to the 
fact that accessible tissue samples are taken for diagnosis or post-mortem. In the recent years several 
laboratories have shown gene expression profiles of extranodal B cell lymphomas including the 
PCNSL 3, allowing their phenotypical characterization. The availability of diffuse large B cell 
lymphomas cell lines that resemble phenotypically the malignant B cells in PCNSL, has allowed us to 
analyze their migratory capacity in response to the chemokines that we show are produced in the 
tumor.   
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Adaptive immune effectors as well as malignant B cells express particular sets of chemokine 
receptors and respond to chemotactic cues. Our data strongly suggests that the vascular and 
perivascular microenvironment in PCNSL may be responsible for CD8+ T cell recruitment, as well as 
for the accumulation of malignant B cells by releasing specific chemokines such as CXCL9 and 
CXCL12. The chemokine coexpression provides synergistic signals to T and malignant 
B lymphocytes. This synergistic activity between CXCL9 and CXCL12 may explain reactive 
perivascular T cell infiltrates and the angiocentric behavior of PCNSL cells. Recent studies confirmed 
the in vivo relevance of chemokine heterocomplexes and show the potential of disrupting their 
functional interactions to attenuate cell recruitment 41. CXCR3-agonists also affect CXCL12-induced 
migration on plasmacytoid dendritic cells, but most likely with a mechanism that does not imply the 
presence of heterocomplexes due to their additional expression of CXCR3.42  
It remains matter of debate whether malignant B cells in PCNSL are recruited from the periphery 
and/or trapped within the CNS. CXCL12 is a potent factor for homing and survival of long lived 
plasma cells in the bone marrow.43,44 It is therefore possible, that the peculiar expression of B cell 
attractant chemokines like CXCL12 and other soluble factors provided by the tumor 
microenvironment may provide a niche-like environment for malignant B cells in the CNS.  
Our findings highlight the importance of distinct regional expression and cellular sources of 
chemokines for the recruitment of TILs, and improve our understanding of both cellular dynamics and 
histological features in PCNSL.  
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Figure Legends 
FIGURE 1. Infiltration and distribution of TILs in 22 cases of PCNSL.  
(A) Immunohistochemical analysis of CD8+, CD4+ and Foxp3+ lymphocytes. TILs are limited to the 
tumor mass (*) (black lines indicate tumor border, positive cells are shown in brown). Scale 
bar: 250 µm. Bottom panels show, for each staining, typical accumulation of TILs mixed with large 
malignant B cells (arrows) in the perivascular areas. Scale bar: 100 µm. Representative pictures are 
shown. (B) Quantitative analysis of tumor-infiltrating CD8+, CD4+ and Foxp3+ TILs. Data are shown 
as lymphocyte number/0.3 mm2 analyzed in three lymphocyte rich areas. (C) Quantitative analysis of 
CD8+ TILs in tumor area compared to peritumoral CD8+ TILs in 5 cases of PCNSL with ample 
peritumoral tissue. CD8+ TILs selectively accumulate in the tumor areas (p<0.01). (D) Quantitative 
analysis of CD8+ TILs in perivascular versus diffuse areas within the tumor mass. CD8+ TILs tend to 
accumulate in the perivascular area within the tumor mass (p<0.05).  
 
FIGURE 2. Phenotypic characterization of TILs in PCNSL. (A) CD8+ TILs express Granzyme B and 
proliferate in situ. Expression of Granzyme B (GrzB, left panel) and Ki67 (right panel) (scale 
bars: 20 µm). Two higher magnifications of positive cells are shown for each staining in the lower 
panels (scale bars: 10 µm). Representative pictures are shown. Approximately half of CD8+ TILs show 
a polarized expression of Granzyme B, whereas about 15% are Ki67+. Pie charts on the right indicate 
the percentage of positive and negative cells in all samples analyzed. (B) A fraction of TILs shares 
phenotypic markers of TFH. Representative pictures of CD3+ TILs expressing CXCL13 (left panel, 
white arrows), CD57 (middle panel, white arrows) and IRF4 (right panel, white arrows). IRF4+ 
malignant B cells are indicated in the right panel with yellow arrows. Scale bars: 20 µm. Two higher 
magnifications of CD3+/CXCL13+, CD3+/CD57+, and CD3+/IRF4+ cells are shown in the lower panels 
(scale bars: 10 µm).  
 
FIGURE 3. CXCL9 is transcribed and translated by the perivascular microenvironment. (A) Analysis of 
CXCL9 mRNA performed by in situ hybridization (left panel) show colocalization with CXCL9 
protein detected by immunohistochemistry (right panel). Scale bars: 100 µm. (B) CXCL9 expression is 
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associated to vascular/perivascular areas (scale bars: 100 µm). (C) Double immunofluorescence 
microscopy shows CXCL9 expression in SMA+ pericytes (top panels), and in CD68+ perivascular 
macrophages/microglia (bottom panels). Scale bars: 40 µm. 
 
FIGURE 4. TILs accumulate in areas with high CXCL9 expression. (A) The CXCL9 positive area was 
calculated as percentage of the total tumor area. The 22 samples were divided in three groups 
according to CXCL9 expression: low (<5%, white), intermediate (>5-20%, light grey) and high 
(>20%, black). (B) Analysis of CD8+ (top panel), CD4+ (middle panel) and Foxp3+ (bottom panel) 
TILs according to CXCL9 expression. TILs accumulate in CXCL9+ tissue. (C) The analysis of 
consecutive slides shows that perivascular CXCL9 mRNA (i,iii), detected by in situ hybridization, is 
associated with CD8+ lymphocytes (ii,iv). Scale bars: 250 µm (i, ii), and 100 µm (iii, iv). (D) CD8+ 
(left panel) and CD4+ (right panel) TILs were counted in positive and negative CXCL9 area in 5 cases. 
CD8+ TILs selectively accumulate in CXCL9 positive area (p<0.01).   
 
FIGURE 5. CXCL9 and CXCL12 are coexpressed in the perivascular microenvironment and can form 
heterocomplexes. (A) PCNSL reactive perivascular T cell infiltrates. Top panel shows a typical 
accumulation of CD3+ TILs in the inner rim and of CD20+ malignant B cells in the outer rim. Lower 
panel shows a vessel on the tumor border with typical accumulation of CD3+ TILs and CD20+ 
malignant B cells in the perivascular cuff. Scale bars: 100 µm. (B) CXCL9 (left panels) and CXCL12 
(right panels) protein expression in the perivascular microenvironment (top panels) and on the tumor 
vasculature (bottom panels). (C) Double immunofluorescence analysis shows colocalization of 
CXCL12 and CXCL9 on PCNSL vessel. (D) CXCL9 forms heterocomplexes with CXCL12. Western 
blot analysis of immunecomplexes identified with anti-CXCL9 and CXCL12 antibodies.   
 
FIGURE 6. CXCL9 enhances CXCL12-induced migration of CD8+ T cells and malignant B cells  
(A) Flow cytometric analysis of CXCR3 and CXCR4 expression, and migratory responses towards 
CXCL9 and CXCL12 of CD8+ T cells. Migrated cells were counted in 5 high power fields and are 
shown as mean±SEM of 3 independent experiments performed with cells from different donors. 
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(B) Migratory responses of CXCR3+CXCR4+CD8+ T cells towards 300 nM CXCL9 (checker bar), 
different concentration of CXCL12 alone (white bars) or in the presence of 300 nM CXCL9 (grey 
bars). Migrated cells were counted in 5 high power fields and are shown as mean±SEM of 
3 independent experiments performed with cells from different donors. (C) Flow cytometric analysis 
of CXCR3 and CXCR4 expression, and migratory responses towards CXCL9 and CXCL12 of 
OCI-Ly10. (D) Chemotaxis assays performed on 4 DLBCL cell lines at sub-optimal CXCL12 
concentration (10 nM) in the absence and presence of 300nM CXCL9. Migrated cells were counted in 
5 high power fields and are shown as mean±SEM of three independent experiments.  
 
Supplementary Figure S1. Expression of CXCL13, CD57 and IRF4 by TFH cells in the light zone of 
the germinal center from human tonsil. Representative pictures of CXCL13, CD57 and IRF4 at three 
different magnifications. (A) CXCL13 is restricted to FDCs, and TFH cells of the light zone of the 
germinal center (left panel). Higher magnification for CD3+CXCL13+ lymphocytes (middle panel, 
white arrows). Two higher magnifications of CD3+CXCL13+ lymphocytes are shown on the right 
panels. (B) CD57 is restricted to TFH in the light zone of the germinal center (left and middle panels, 
white arrows). Two higher magnifications of CD3+CD57+ cells are shown on the right panels. (C) 
IRF4 is expressed by CD3+ T cells (white arrows), as well as B cells (IRF4high ) mostly in the light 
zone of the germinal center (left and middle panels). Two higher magnifications of CD3+IRF4+ 
lymphocytes are shown on the right panels. Scale bars: white 40µm, green 10µm. 
 
Supplementary Figure S2. Chemokine receptor profiles and surface markers for different 
DLBCL cell lines.  
Cytofluorimetric analysis of the 4 different DLBCL cell lines used (OCI-Ly7, OCI-Ly10, OCI-Ly19, 
SU-HDL6) for phenotypic markers. Color code shows absence (green), low (yellow) or high (red) 
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5. DISCUSSION 
5.1 B cell attractant chemokines in secondary lymphoid organs  
Understanding chemokine-guided immune responses is subject of intense research and many questions 
remain to be resolved. Previous work on human samples and in murine models has investigated the 
role of T and B cell attractant chemokines and has greatly improved our understanding of lymphocyte 
trafficking within secondary lymphoid organs. Studies on lymphocyte trafficking in secondary 
lymphoid organs have been mainly performed in murine models. The work presented here has been 
entirely performed on human tissue samples and describes in more detail the expression of B cell 
attractant chemokines, CXCL12 and CXCL13, and of the inflammatory chemokine CXCL9 in 
secondary lymphoid organs under homeostatic and inflammatory conditions, as well as in B cell 
maligancies at extranodal site.   
Recent work in murine infection models have revealed downregulation of homeostatic CCL21 and 
CXCL13 under acute inflammatory conditons, which leads to disruption of lymph node 
architecture.(283,284) Our date show a  clear gradient of CXCL13 between the dark and the light zone 
of the germinal center. Interestingly, the majority of the TFH cells expressing CXCL13 are located at 
the border between the ligh zone of the germinal center and the mantle zone. Yet, they represented 
only a minority of follicular T cells, indicating the presence of different T cell subtypes or 
upregulation of CXCL13 during a distinct time point within the germinal center.  It is well known, that 
TFH cells provide help to B cells in the light zone of the germinal center, but whether germinal center 
B cells also play a role in the differentiation of follicular T cells remains to be clarified.  
Beside CXCR5, the chemokine receptor for CXCL13, CXCR4 is a classical B cell chemokine receptor 
and is constitutively expressed on normal and malignant B cells. We analyzed the expression of its 
ligand, CXCL12, in human secondary lymphoid organs.  
The reticular network of epithelial cells in the tonsillar crypts, creates a mesh in which B cells and 
plasma cells are in close proximity to incoming antigens.(288) We have observed a high expression of 
CXCL12 by tonsillar crypt epithelial cells that may account for a significant CXCL12 gradient 
between underlying B cell follicles and the crypt epithelium. Plasma cells and memory B cells which 
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have been generated in the light zone of germinal centers underlying the crypt epithelium, upregulate 
CXCR4 during late B cell differentiation.(76,92) They may sense a CXCL12 gradient outside the 
germinal center and migrate towards the epithelium of the tonsillar crypts. This hypothesis is also 
supported by the finding that CD138+ plasma cells generated within the germinal center align at the 
germinal center border underlying the crypts. It is tempting to hypothesize, that plasma cells and 
memory B cells generated in the germinal centers traffick towards the tonsillar crypt, where they 
encounter a niche like-environment build up by CXCL12 expressing epithelial cells. CXCL12 
expression in normal lymph nodes was mainly found in the subcapsular sinuses. In line with the crypt 
epithelium in the tonsil, the subcapsular sinus is exposed to incoming antigens. Shuttling of follicular 
B cells towards the sinus where they take up antigen from subcapsular macrophages has been recently 
reported by several groups.(289,290) Our findings in human lymph nodes indicate, that CXCL12 
expression in the subcapsular sinuses may play an important role in a B cell shuttling towards the 
subcapsular sinus. Of interest, we have found that CXCL12 mRNA expression is downmodulated 
upon inflammation, whereas protein levels remain confind to vessels, subcapsular sinuses, and in the 
GC. The role of CXCL12 inside the germinal center needs further investigation. Our findings reveal, 
that the CXCL12 expression in the T area is generally more abundant than in GC. GC-derived 
CXCL12 was mainly found on highly phagocytic tingible body macrophages. Whether the CXCR4-
CXCL12 axis between tingible body macrophages and GC B cells is important in phagocytic activity 
is currently unknown. The finding that CD20+ B cells in the T area accumulate around CXCL12-
expressing HEVs is in line with a previous report in the mouse.(126) Yet, the phenotype and the role 
of perivascular B cells around CXCL12-expressing HEVs in secondary lymphoid organs need further 
characterization. Interestingly, malignant B cells in PCNSL also tend to accumulate around CXCL12-
expressing vessels and it is tempting to hypothesize that perivascular B cells around HEVs and 
malignant perivascular B cells in PCNSL share angiocentric behaviour due to common genetic 
programs. It remains to be clarified, whether perivascular B cells around HEVs are pre- or post-GC 
B cells. Of special interest is the coexpression of CCL21 and CXCL12 in the T area. This finding 
highlights the fact, that T and B cells in the T area of secondary lymphoid organs are simultaneously 
exposed to several chemokines and adds a new level of complexity to lymphocyte trafficking. 
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Lymphocyte movement within the T area may therefore be regulated by minor changes in CCL21 and 
CXCL12 chemokine expression between stromal cells. Coexpression of chemokines at low 
concentrations may overcome higher concentrations of a single chemokine. In addition, coexpression 
of homeostatic chemokines by stromal cells may regulate trafficking of different immune effectors to 
the same area. 
CXCL9 as a classical inflammatory chemoattractant for T cells and plasma cells was found in distinct 
areas within the T cell area of inflamed tonsils. CD8+ T cell accumulation could be observed in these 
distinct areas. This is a strong indicator that CD8+ T cell distribution in the T area is at least partly 
regulated by CXCL9 expression in the environment. While previous work in the mouse has described 
CXCL9 expression on HEV, which induces CD8+ T cell recruitmen into secondary lymphoid organs 
(97), we could not detect CXCL9 on HEVs. Its expression was restricted to cells in the parafollicular 
area with dendritic cell-like morphology. The receptor for CXCL9, CXCR3 is classically expressed on 
activated CD4+ T cells and the majority of CD8+ T cells. CD4+ T helper cells are well known for their 
role in providing critical signals during priming of cytotoxic CD8+ T lymphocytes. These interactions 
take place in the T cell area of secondary lymphoid organs. CXCL9 expression by dendritic cells in the 
T area may therefore be a good chemokine candidate to bring recently activated CD4+ T cells in close 
contact with CD8+ T cells.  
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5.2 B and T cell attractant chemokine environment in PCNSL  
PCNSL is a poorly understood extranodal CNS lymphoma mainly due to limited access to tissue and 
the lack of animal models. This study focused for the first time primarily on the tumor 
microenvironment, with special emphasis on the the chemokine environment and the potential impact 
on the recruitment of adaptive immune effectors into PCNSL.  
In this work, we analyzed in detail the lymphocyte subsets in PCNSL, and the role that different T and 
B cell attractant chemokines might have in regulating their recruitment. We have found that TILs 
consist of a heterogeneous population of T cells, including CD8+, Granzyme B+ T cells showing an 
activated phenotype and T cells which share phenotypic marker of TFH in the germinal center, 
indicating that a fraction of TILs may provide help to malignant B cells.  
The chemokine environment showed upregulation of different B and T cell attractant chemokines, 
such as CXCL9, CXCL12 and CXCL13 in PCNSL microenvironment. These chemoattractans 
modulate migratory behaviour of lymphocytes expressing their cognate receptors CXCR3, CXCR4 
and CXCR5. Previous reports have shown that malignant B cells in PCNSL are typically positive for 
CCR7, CXCR4 and CXCR5.(108) This chemokine receptor profile is also found on antigen 
experienced B cells, which upon activation upregulate CCR7 but do not downregulate CXCR4 and 
CXCR5.(129) While we could detect CCR7 expression in half of the cases, CCL21 could not be 
detected within PCNSL. In contrast, the finding that the two B cell attractant chemokines CXCL12 
and CXCL13 are expressed by activated macrophages/microglia in PCNSL indicates that there is a 
crosstalk between macrophage/microglia-derived chemokines and malignant B cells. CXCL12 is 
known to play a central role in trapping of hematopoietic stem cells, B cell precursor and plasma cells 
in the bone marrow.(67-71) (74,75) In addition, CXCL13 regulates B cell trafficking of germinal 
center B cells.(33,76) The release of these two B cell chemoattractant in the PCNSL 
microenvironment may strongly influence the behavior of malignant B cells in PCNSL.  It is tempting 
to hypothesize, that the inflammatory responses in the CNS during PCNSL may create a niche-like 
environment for malignant B cells. Of note, the presence of chemokines induces activation of integrins 
such as LFA-1 and VLA-4 in normal B cells. It will therefore be important to investigate whether the 
inflammatory CNS environment in PCNSL expresses the cognate ligands for B cell integrins, such as 
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ICAM-1 and VCAM1. ICAM-1 expression by activated microglia may enhance B cell adhesion. 
Previous reports have shown that activated microglia express ICAM-1.(291,292) FDCs in germinal 
center light zone also express ICAM-1 and VCAM-1 and the interaction of LFA-1 and VLA-4 on 
germinal center B cells have been shown in vitro to prevents them from undergoing apoptosis.(293) 
Upregulation of CXCL12 and CXCL13 has also been described in other CNS pathologies (294-297), 
such as multiple sclerosis, indicating their potential role in inflammatory CNS conditions. While 
upregulation of CXCL12 and CXCL13 in the CNS microenvironment during the course of an 
infection may be important to attract and trap normal B cells in the CNS, the presence of a malignant 
proliferating B cell clone may induce a positive feedback mechanism, which drives tumor expansion 
by inducing peritumoral edema which leads to the activation of peritumoral microglia, upregulation of 
chemoattractants and subsequent migration of malignant B cells towards activated microglia in the 
peritumoral space. 
 
Model for perivascular accumulation of infiltrating CD8+ T cells and angiogenctric behaviour of 
malignant B cells in PCNSL. Vascular and perivascular CXCL9 and CXCL12 found on endothelium and 
pericytes act in an additive and synergistic way on infiltrating T cells and malignant B cells.   
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This scenario is supported by the finding, that peritumoral microglia stains positive for CXCL12. In 
addition to a previous report from the laboratory, that has found CXCL13 expression by malignant 
B cells in PCNSL (203), we found here that also activated microglia/macrophages as well as 
infiltrating T cells express CXCL13. Microglial cells share morphological and functional features of 
dendritic cells and are able to present antigen to lymphocytes. This raises the question whether there 
are parallels between CXCL13-expressing follicular dendritic cells during germinal center reactions 
and CXCL13-expressing activated microglia in PCNSL. In addition, we found TILs expressing 
CXCL13, a typical feature for TFH cells in the light zone of germinal centers.  FDCs and TFH cells play 
a key role during late germinal center reaction and provide costimulatory signals to late germinal 
center B cells which support their survival. (79) Whether proliferating malignant B cells are able to 
influence their CNS microenvironment is currently unknown and requires further investigation.  
While CXCL12 and CXCL13 show a scattered expression pattern within PCNSL, CXCL9 is 
specifically expressed in perivascular areas around small and intermediate size vessels by perivascular 
macrophages/microglia. Its distinct expression pattern within the tumor could therefore regulate 
recruitment and trapping of TILs and malignant B cells in the perivascular cuff. The finding that 
CXCL9 expression correlates with CD8+ T cell recruitment to PCNSL indicates its role in the 
attraction of adaptive immune effectors to the CNS. Although CD8+ TILs represent the major T cell 
subset in PCNSL, CD8+ T cell recruitment into PCNSL shows variations among different patients. 
This might be due to a reduced CXCL9 expression in the perivascular area. Our findings support the 
idea, that perivascular macrophages/microglia plays an important role in the recruitment of adaptive 
immune effectors to PCNSL. It remains to be determined, whether perivascular 
macrophages/microglia are activated in an antigen-specific or cytokine-driven manner. In contrast to 
CXCL12 expression, we could not find CXCL9 upregulation and CD8+ T cells outside the tumor 
mass, indicating that TILs access the tumor via inflamed vessels inside the tumor. Interestingly we 
found that CXCL12 and CXCL9 can be coexpressed on vessels within PCNSL and could therefore 
simultaneously act on circulating T lymphocytes as well as on resident malignant B cells via CXCR3 
and CXCR4. A histopathological peculiarity of PCNSL is the angiocentric behaviour of malignant 
B cells and reactive perivasular T cell infiltrates. Our in vitro findings reveal that coexpressed CXCL9 
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and CXCL12 on tumor vessels synergize on malignant B cells to induce stronger migratory responses 
and lead to perivascular accumulation of malignant B cells. Circulating CD8+ T cells did not show 
synergistic, but rather additive migration capacity towards simultaneous exposure to CXCL9 and 
CXCL12. These findings support a model, in which vascular and perivascular expressed CXCL9 and 
CXCL12 act in a synergistic way in malignant B cells and on an additive way on infiltrating CD8+ 
T cells and build up an inner rim of T cells and an outher rim of malignant B cells and therefore 
angiocentric behaviour. Our findings highlight the importance of distinct regional expression of 
chemokines in PCNSL, and improve our understanding of cellular dynamics and histological features 
in this tumor.  
It remains matter of debate whether perivascular malignant B cells are recruited from the periphery or 
are relocated in areas due to a particular chemokine environment in the perivascular cuff.  
 
5.3 Adaptive immune responses in PCNSL 
Our results reveal that adaptive immune effectors from different T cell subsets are recruited to PCNSL 
and show different phenotypes. Tumor-infilatrating CD8+ T cells represent the major T cell subset in 
PCNSL. Proliferating CD8+ T cells are numerous and are a strong indication for TCR-mediated 
recognition and activation-induced proliferation. In certain cases, the number of proliferating 
Ki67+CD8+ was comparable to the number of proliferating tumor cells. Yet, we can not formerly 
prove that CD8+ TILs specifically kill malignant B cells in an antigen-specific manner in PCNSL, 
because their activation may be cytokine-driven but antigen independent. The isolation of CD8+ TILs 
from tissue to analyze their killing activity will be a difficult and challenging task due to the lack of 
sufficient tissue. Nevertheless, the large number of CD8+ T cells in many PCNSL cases remains rather 
surprising, taking into account the poor prognosis of this tumor. Our results reveal that the adaptive 
immunity might be able to mount a specific cytotoxic immune response against PCNSL, indicated also 
by the high numbers of apoptotic cells in situ within the tumor mass (data not shown). Nevertheless, 
the adaptive immune response is not sufficient to appropriately counterbalance tumor growth. In 
addition, CD8+ T cell recruitment is typically seen in various viral infections. Despite the fact that all 
investigated PCNSL cases were negative for EBV, other viral pathogens cannot be excluded. Analysis 
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of clonality and TCR specificity of tumor infiltrating CD8+ T cells may shed new light into their 
specific antitumoral function in PCNSL. Despite being the most prominent T cell subset in PCNSL, 
tumor-infiltrating CD8+ T cells varied significantly between patients. Of note, patients with low CD8+ 
T cell infiltration showed low or no CXCL9 expression, indicating that activated perivascular 
macrophages/microglia and pericytes may have a central role in CD8+ TIL recruitment. A recent 
report in a mouse model describes CD8+ T cells recruited to the lymph node via CXCL9. These CD8+ 
T cells kill antigen presenting cells and in this way limit the ability of dendritic cells to activate 
additional T cells.(97) It is therefore also possible that a higher ratio of CD8+ TILs may dampen the 
antitumor immune response. Further investigation is needed to verify the effect of tumor-infiltrating 
CD8+ T cells in counterbalancing PCNSL.  
Compared to CD8+ T cells, intratumoral CD4+ lymphocytes are less abundant and their distribution 
within the tumor mass does not reflect CD8+ T cell infiltration and CXCL9 expression. This finding 
indicates that alternative chemotactic cues might be responsible for CD4+ T cell recruitment to 
PCNSL. Interestingly, numerous TILs show IRF4 expression indicating TCR-mediated activation and 
differentiation towards Th2 or Th17.(167,298,299) A recent report highlighted the importance of Th2 
cell help for the development of lymphomas in a mouse model.(300) Those large B cell lymphomas 
are also IRF4+, as PCNSL (197), and developed consistently at extranodal sites.(300) It is tempting to 
hypothesize that a subset of TILs represent TFH-like phenotypes and can provide costimulatory and 
antiapoptotic signals, or modulate the activity of AID, similar to TFH cells in the light zone of the 
germinal center. Future studies are needed to investigate the clonality and TCR specificity of tumor 
infiltrating CD4+ T cells to assess their potential tumor-promoting activities. 
It has been previously shown, that the B cell attracting chemokine-1, CXCL13 is constitutively 
expressed in secondary lymphoid organs, in the light zone of the germinal center by FDCs and TFH 
cells(24,301), as well as under several pathological conditions.(24,110,203,296) We show that 
CXCL13 is also expressed by activated microglia/macrophages as well as by a fraction of TIL. Further 
characterization of T cell subsets and their specific function will be important to distinguish between 
tumor-suppressive and tumor-promoting T cell activities.  
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A recent gene expression study reported a strong upregulation of the extracellular matrix molecule 
Osteopontin in PCNSL cases.(287) Interestingly, Osteopontin similar to CXCL13, is expressed in the 
light zone of germinal centers. It remains to be determined, whether malignant proliferating B cells 
can educate their environment to produce soluble factors or upregulate costimulatory signals on 
infiltrating T cells, to build up a germinal center-like environment.  
 
5.4 Outlook 
The data presented here has been performed entirely on human tissue samples. This underlies its 
relevance for human immunology and human immunopathology. The availability of PCNSL murine 
models would help verifying our hypothesis and perform proof of principle studies. Distinct 
expression of CXCL12 by subcapsular macrophages reveals a role as chemoattractant towards the 
subcapsular sinus. This gradient may be responsible for B cell shuttling to the subcapsular sinus, 
where B cells can pick up antigens from subcapsular macrophages.(289,290) B cell shuttling towards 
the subcapsular sinus may be reduced by specific inhibition of CXCR4.  
A better understanding of germinal center reactions as the cradle for plasma cell and memory cell 
development requires special attention. On one hand to improve our knowledge on the generation and 
maintenance of immunological memory and on the other hand to improve our understanding on 
germinal center derived B cell malignancies. We showed here that there are paralles between the light 
zone of the germinal center and the tumor microenvironment in PCNSL, such as the presence of 
CXCL12 and CXCL13 expressing myeloid cells and the presence of CXCL13 expressing T cells, The 
mutual interactions between germinal center B cells and the germinal center environment is not fully 
understood yet and it remains to be determined whether germinal center B cells are able to instruct the 
germinal center environment, such as FDCs and TFH cells. GC-derived B cell malignacies may also 
have the capacity to induce GC-like properties in their environment, which support their survival in a 
niche-like environment.   
The role of germinal center CD8+ T cells remains unknown. They are less numerous compared to 
CD4+ T cells in the germinal center, but present in almost all germinal center reactions. Why are some 
CD8+ T cells able to migrate into the GC, whereas the majority is not and what is their role within the 
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germinal center? Our data in inflamed secondary lymphoid organs reveals that CXCL9 plays an 
important role in CD8+ T cell distribution in the T area. Future studies on lymphocyte trafficking may 
have to distinguish between lymphocyte recruitment to the tissue and distribution of lymphcytes 
within a given tissue.  As presented here, simultaneous coexpression of different chemokines is not an 
exception, but rather common, particularly under inflammatory conditions. The mechanisms how 
lymphocytes integrate simultaneous signals from different chemokines needs to be investigate, as well 
as the ability of chemokines to form heterocomplexes and induce stronger migratory responses in vivo. 
Further studies in PCNSL may focus on role of the inflammatory CNS microenvironment as niche for 
malignant B cells. Chemokines such as CXCL12 are known to induce inside-out signals to induce 
activation of integrins by conformational changes, which leads to tight binding of lymphocytes to cells 
expressing the appropriate integrin ligands. Special focus should be given to the crosstalk between 
malignant B cells and activated microglia/macrophages. 
 
 
5.5 Concluding remarks 
This study adds valuable and important data on the crosstalk between the tumor microenvironment and 
malignant B cells in the CNS. The results presented here describe the chemokine environment in 
PCNSL and its potential implication on intracerebral tumor expansion, as well as on the recruitment of 
adaptive immune effectors to the tumor. B cell chemoattractants such as CXCL12 and CXCL13 are 
expressed by the inflammatory microenvironment, while malignant B cells in PCNSL express the 
cognate receptors CXCR4 and CXCR5 and are therefore capable of responding to the ligands in the 
microenvironment. These findings reveal a direct crosstalk between activated microglia/macrophages 
and malignant B cells in PCNSL and indicate a potential niche-like environment for malignant B cells 
in the inflamed CNS. Blocking these interactions by specific inhibitorsn such as a CXCR4 antagonist 
(AMD3100), may disrupt CXCL12-induced effects on malignant B cells and inhibit CXCL12-
dependent expansion. Our results refer to PCNSL but may also be valid for other CNS diseases where 
inflammatory cells accumulate in the perivascular area. The results presented here highlight the 
importance of distinct analysis of bystander cell types present in a given malignancies to better 
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understand its seeding behavior. In this regard, gene expression studies on whole tissue samples may 
be misleading in terms of interpretation.  
The immune system is likely to play an important role in PCNSL, given the fact that 
immunosuppressed patient have a higher risk for PCNSL. Adaptive immune responses in PCNSL 
seem to be elicited in the majority of the cases. We described various T cells subsets in PCNSL with 
potential tumor suppressive as well as tumor promoting properties. A difficult but important task will 
be to discriminate different T cell subsets in the tumor, and to address their tumor promoting or tumor 
suppressive effects.  Regulatory T cells do not seem to play a major role for tumor escape in PCNSL, 
nevertheless, the presence of TFH-like T cells within the tumor may provide tumor supporting signals. 
The simultaneous coexpression of chemokines in the tumor microenvironment and their synergistic 
activites on malignant B cells adds an additional level of complexity.  
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